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Abstract 
 
Influenza is a serious respiratory virus in terms of global morbidity and mortality. Patients 
hospitalized with influenza generally have comorbidities contributing to their disease severity 
and are most at risk for further severe influenza-related outcomes. Despite the importance of this 
group, there are few studies investigating interventions in populations of patients hospitalized 
due to influenza. Specifically, robust evaluation is needed of the two most used interventions 
against severe influenza, vaccination and neuraminidase inhibitors. The best available protection 
against influenza illness is vaccination, which is recommended annually in the United States and 
in many other countries worldwide. Treatment with neuraminidase inhibitors has been shown to 
prevent severe influenza outcomes and reduce symptomatic illness; antiviral treatment is 
recommended for all hospitalized patients with suspected or confirmed influenza in the United 
States.  
This dissertation examines two components of prevention of severe influenza: vaccine 
effectiveness against hospitalization, and the prevention of severity in individuals at high risk for 
severe influenza outcomes. Influenza vaccine effectiveness against hospitalization of Israeli 
children who are fully or partially vaccinated was determined through use of medical record data 
over three influenza seasons in chapter 2. Vaccination was found to be effective for fully, but not 
partially, vaccinated children over all three seasons. This result supports guidelines by the 
Advisory Committee on Immunization Practices in the United States and the Israeli Ministry of 
Health, which recommend two inoculations in the first season of vaccination for children under 
nine years of age. 
 xiii 
In chapter 3 we focused on the methodological validity of the test negative design in the 
inpatient setting. We tested specimens previously collected for vaccine effectiveness estimation 
against hospitalization in adults participating in the HAIVEN study for a variety of respiratory 
viruses. We calculated VE in three ways: using the traditional influenza-negative control group, 
using an influenza negative but other virus positive control group, and using a pan-negative 
control group, in order to evaluate whether inclusion of individuals without a true ARI in the 
influenza-negative control group biases VE estimates in the hospital. We did not find consistent 
differences in VE by control group, suggesting that this bias is not a persistent problem when 
estimating vaccine effectiveness against hospitalization.  
In the next two chapters, we focused on characterization of influenza severity and risk 
factors for severe influenza. In chapter 4 we studied adults hospitalized with influenza over two 
seasons. Using inverse probability weighted logistic and linear models, we found that rapid 
antiviral treatment was associated with reduced odds of lower pulmonary disease and that obese 
patients were treated more rapidly with antiviral medication than non-obese patients, making 
antiviral treatment timing a potential confounder of the relationship between obesity and severe 
influenza. In chapter 5, we evaluated predictors of ICU admission, 30-day readmission, and 
extended length of stay among hospitalized adults over two seasons of the HAIVEN study.  
Frailty and lack of prior year health care visits were associated with reduced influenza and acute 
respiratory infection severity. Through linear models stratified by vaccination status, we found 
that antiviral treatment was associated with reduced hospital length of stay in vaccinated, but not 
unvaccinated patients. Ongoing research to measure the underlying disease severity in these 
groups at presentation to the hospital will aid in further interpretation of this result.
 1 
Chapter 1 Introduction 
 
In this dissertation, I will explore predictors and prevention of severe respiratory 
infection and influenza virus infection specifically among hospitalized individuals. In chapter 1, I 
discuss the impact of influenza and other respiratory viruses on human health, and the 
importance and difficulties of studying acute respiratory infection in hospitalized individuals. 
Throughout the dissertation, I examine the effectiveness of the influenza vaccine in preventing 
severe influenza infection, focusing on the effectiveness of influenza vaccine at preventing 
disease in understudied groups as well as the validity of using common methods for calculating 
vaccine effectiveness among hospitalized individuals. I also discuss which hospitalized 
individuals are most at risk for severe influenza outcomes and what interventions can help 
prevent these disease manifestations. Further, I suggest new methods to more accurately conduct 
these studies to be used in the future. 
1.1 Specific Aims and Hypothesis 
The specific aims and hypotheses addressed by this dissertation are: 
Aim 1. Estimate influenza vaccine effectiveness among hospitalized Israeli children who are 
fully or partially vaccinated according to the Advisory Committee on Immunization Practices 
(ACIP) and Israeli Ministry of Health. 
Hypothesis 1. Influenza vaccination according to the ACIP and Ministry of Health guidelines 
will be significantly protective against influenza. Vaccine effectiveness of partial vaccination 
will be lower than that of full vaccination. 
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Aim 2.  Estimate influenza vaccine effectiveness using alternate control groups (all influenza 
negative, influenza negative and other respiratory virus positive, negative for all viruses) to 
determine if an over inclusion of individuals with a non-infectious illness is biasing influenza 
vaccine effectiveness estimates among hospitalized adults.  
Hypothesis 2. Influenza vaccine effectiveness using alternate control groups will be significantly 
lower than vaccine effectiveness estimates using pan-negative or the traditional influenza-
negative control groups, indicating bias due to inclusion of individuals in the study without an 
infectious illness. 
Aim 3. Determine whether obesity, previously identified as a predictor of severe influenza, was 
associated with severe outcomes among hospitalized adults in Detroit, Michigan. Also evaluate 
the impact of neuraminidase-inhibitor administration on severe influenza outcomes. 
Hypothesis 3. Obese individuals will have increased odds of severe disease manifestations, 
including increased hospital length of stay, increased odds of lower pulmonary disease, and 
increased odds of intensive care unit admission. 
Aim 4. Determine predictors of severe influenza and acute respiratory infection related outcome 
among hospitalized adults, such as increased hospital length of stay, ICU admission, and 
mechanical ventilation. Estimate the impact of influenza vaccination and neuraminidase inhibitor 
administration on severe influenza outcomes. 
Hypothesis 4. Older individuals, individuals with more comorbid conditions, and individuals 
who are more frail will have increased severe manifestations of influenza. Influenza vaccination 
and early administration of neuraminidase inhibitors will be associated with a reduction in severe 
outcomes. 
1.2 Background and Significance 
Viral respiratory infections are an important cause of morbidity and mortality globally 
among individuals of all ages1,2. Influenza, influenza like illness (ILI), and pneumonia together 
comprise the eighth most common cause of death in the United States3. While influenza is a 
major cause of morbidity and mortality during the Winter, a variety of respiratory viruses 
circulate during the influenza season and cause illness that is  clinically indistinguishable from 
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influenza, including: respiratory syncytial virus (RSV), human coronaviruses (hCVs), 
parainfluenzaviruses (PIV), adenovirus (AV), human metapneumovirus (HMPV), and rhinovirus 
(RV)4–6. In addition to the morbidity burden caused by these viruses, the economic burden of 
these infections is also not trivial. It has been estimated that the direct and indirect costs of non-
influenza viral respiratory infection approach $40 billion in a single year in the United States7.  
Despite the importance of non-influenza viruses, particular attention is devoted to studying 
influenza viruses due to the impact that these viruses have on morbidity and mortality; influenza 
viruses were estimated to cause 48.8 million illnesses, 959,000 hospitalizations, and 79,400 
deaths in the United States during the 2017-2018 season8. In addition, influenza viruses are 
characterized by frequent genetic changes that are reflected in antigenic changes, meaning that 
antigenically distinct influenza viruses circulate each season and that individuals may be 
susceptible to influenza infection from the same influenza subtype in consecutive seasons. 
Periodically, novel influenza A viruses can emerge, leading to influenza pandemics9,10. The most 
recent influenza pandemic in 2009 was caused by the emergence of the influenza 
A(H1N1)pdm09 subtype which now circulates seasonally. In comparison with previous 
pandemics, the 2009 influenza pandemic was mild, but still there were an estimated 12,000 
deaths and 300,000 hospitalizations associated with this emergence of a new influenza strain, 
indicating the huge impact that even a “mild” influenza pandemic can have on human health11. 
Influenza vaccination is the most effective way to prevent influenza; treatment with 
neuraminidase inhibitors is also recommended to reduce adverse outcomes of influenza infection 
and to shorten illness duration in cases of severe influenza or cases of influenza among 
individuals at high risk for adverse outcomes12. While these methods are routinely used to 
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prevent and treat seasonal influenza, it is also key to understand their effectiveness in order to 
quickly develop potent vaccines and antiviral drugs in the case of an influenza pandemic.  
As mentioned previously, the most effective way to prevent influenza infection is through 
vaccination. The influenza vaccine is recommended for all individuals 6 months and older in the 
United States and in many other countries around the world, including Israel13,14. Due to seasonal 
variation in circulating influenza strains, new vaccines are made each season and vaccination is 
recommended each season. Children from age 6 months through 8 years are recommended to 
receive two influenza vaccines the first time that they are vaccinated13. The universal influenza 
vaccination recommendation means that it is not ethical to conduct randomized control trials to 
estimate vaccine effectiveness (VE), as one cannot ethically allocate a study participant to a “no 
vaccination” group. For this reason, numerous observational studies across the world are 
designed to estimate influenza vaccine effectiveness at preventing medically attended illness 
annually15–19.  
Throughout this dissertation, we examine two components of prevention of severe 
influenza: vaccine effectiveness against hospitalization, and the prevention of severity in 
individuals at high risk for severe influenza outcomes. 
1.2.1 Test Negative Design  
The observational study design most commonly used to estimate influenza VE is the test 
negative design (TND)20,21. Generally, studies that use this design are embedded in an influenza 
surveillance system, and prospectively identify patients with acute respiratory infection (ARI) 
symptoms or influenza like illness (ILI) when they present for medical care due to their illness. 
In most cases, information is collected from the medical record and from a brief enrollment 
interview about the participant’s vaccination status, comorbid conditions, and illness course. In 
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addition, a respiratory swab is collected either by the research team or clinical team and tested 
for influenza by reverse-transcriptase polymerase chain reaction (RT-PCR).  Individuals who test 
positive for influenza are considered cases and individuals who test negative are controls. As the 
main exposure of this study is vaccination, confirmation of accurate vaccination status is a key 
part of the study protocol. In countries without centralized medical record data, such as the 
United States, numerous efforts are made to confirm vaccination status, which can involve 
contacting outside medical systems, pharmacies, and a variety of vaccination records.  VE is 
calculated by comparing odds of vaccination between influenza positive and influenza negative 
participants, and it is expressed as (1- ORvaccination) *100. 
The theoretical underpinnings and assumptions in the test negative design have been 
described in a variety of manuscripts22–26. While traditional cohort studies can be used in lieu of 
TND studies to follow individuals throughout the entire influenza season, catching all influenza 
positive participants upon illness onset, this is not an efficient way to calculate influenza VE as 
most people will not be infected with influenza, and many will not experience any type of 
respiratory illness. The TND avoids this inefficiency by detecting influenza positives upon 
presentation for medical care due to a respiratory illness.  
Jackson et al. published a formal methodological description of the TND in 201327. In it, 
they divide the population into two groups of individuals, those who would seek care if they had 
an ARI and those who would not. They explain that because the test negative design enrolls 
participants who have presented to a doctor for medical care, a traditional cohort study, in which 
a cohort of individuals in a certain catchment area are the study subjects, cannot be used. Bias 
due to health care seeking behavior would be a major problem in this scenario, as health care 
seeking behavior is related to both vaccination status and detection of influenza if only 
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individuals who seek care can be cases. The TND solves this problem by restricting enrollment 
to individuals who seek care; effectively ensuring that care seeking behavior is the same in case 
and control groups. As Jackson et al. explain, individuals who would seek care if they had an 
ARI fall into three categories: those who have influenza, those who have a non-influenza 
respiratory infection, and those who do no have a respiratory infection and are therefore not 
currently seeking care for an ARI (Figure 1.1). In this scenario, n1 represents the total number of 
vaccinated individuals who seek care for ARI and n3 represents the number of unvaccinated 
individuals who seek care. Vaccinated individuals who would seek care if they had an ARI who 
are infected with influenza, infected with a non-influenza virus, or not infected with a viruse are 
represented by a, b, and c, respectively. Those who are unvaccinated are represented by d if they 
are infection with influenza, e if they are infected with a non-influenza virus, or c if they do not 
have an infection. Ideally, vaccine effectiveness could be calculated using a risk ratio comparing 
the risk of influenza among vaccinated and unvaccinated individuals. In this case, VE = 1− ! !!! !! ∗ 100. However, n1 and n3 cannot be calculated in this scenario; the number of 
individuals who fall into groups c and i is unknown, as these individuals are not seeking care 
because they do not have a respiratory infection currently (Figure 1.1). Instead, the assumption is 
made that the incidence of non-influenza ARI is not different between the vaccinated and 
unvaccinated population, that 𝑏 𝑛! =  ℎ 𝑛!, indicating that ℎ 𝑏 =  𝑛! 𝑛!. Following this 
assumption, VE = 1−  !∗!!∗! ∗ 100, this is equivalent to (1- ORvaccination) * 100.  
In addition to the assumption that the influenza vaccine does not impact the incidence of 
non-influenza ARI, the validity of TND also depends on various other assumptions. One key 
assumption is that the rate of influenza ARI must vary proportionally with the rate of non-
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influenza ARI across health care seeking thresholds27. If this condition is not met, the study will 
be biased by health care seeking behavior, this bias will only be eliminated by adjustment for 
health care seeking behavior26. In addition, it is important to note that the influenza vaccine is 
hypothesized to reduce influenza severity as well as incidence28,29. If this is the case, vaccine 
effectiveness against medically attended influenza is not a direct measurement of protection from 
infection. Furthermore, if disease severity also differs by influenza status, in addition to being 
related to health care seeking behavior and vaccination, then this may lead to confounding, 
necessitating adjustment for illness severity20. 
1.2.2 Influenza Vaccine Effectiveness against Hospitalization  
The test negative design was first implemented in studies measuring VE against 
medically attended influenza in outpatient clinics. Most of the validation of this study design has 
occurred in this setting. However, hospitalized individuals, who have already experienced an 
adverse outcome due to their influenza infection, are especially vulnerable to further 
complication including necessity for mechanical ventilation, admission to an intensive care unit 
(ICU), or even death. For this reason, understanding the efficacy of vaccination in this 
population is particularly important. Certain subsets of hospitalized patients are particularly 
understudied. The majority of all TND studies occur in countries or regions with well-established 
networks, such as Canada, Australia, the United States, and many countries across Europe, and 
most other countries either have very few or no understanding of their local and regional VE18,30–
33. Hospitalized children are also understudied, with few networks producing VE estimates 
against hospitalization in children annually34–38. In addition, while there is some evidence to 
suggest that two influenza vaccines provide increased protection compared to one vaccine in 
vaccine naïve children, the impact of receiving full influenza vaccination on prevention of 
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hospitalization in children is not fully understood39–42. In chapter two, I address this limitation by 
estimating influenza VE against hospitalization in Israeli children, a previously unstudied 
population. 
 Hospitalized populations vary quite significantly from populations of outpatients: 
hospitalized patients are older and have more comorbid conditions than outpatients. Due to the 
differences between these populations, it is possible that some of assumptions made ensuring the 
validity of the TND in the outpatient setting may not follow in the hospital43,44. For example, due 
to the high prevalence of comorbid conditions among hospitalized patients, some of the patients 
in the influenza negative group may not have a true ARI, but a non-infectious exacerbation of a 
chronic condition such as congestive heart failure (CHF) or chronic obstructive pulmonary 
disease (COPD). If these individuals with more chronic conditions seek medical care at a lower 
threshold than others and are also more likely to be vaccinated, this would bias the VE estimates. 
Despite this potential bias, due to the importance of understanding VE against hospitalization, 
numerous studies produce annual influenza VE estimates against vaccination in this 
setting19,45,46. In chapter three, I use alternate control groups, including one group of patients with 
a PCR confirmed non-influenza infection, to evaluate whether inclusion of patients without an 
ARI is biasing our study, the data used to evaluate this aim come from the HAIVEN study. 
1.2.3 The HAIVEN Study 
The Hospitalized Adult Influenza Vaccine Effectiveness Network  (HAIVEN) study is a 
CDC-funded study conducted at University of Pittsburgh, Vanderbilt University, Baylor Scott 
and White, and the University of Michigan19. In this study, adults hospitalized with an ARI are 
enrolled and a TND protocol is used to calculate influenza VE against hospitalization. Before the 
official creation of HAIVEN during the 2015-16 season, the same protocol was used only at the 
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University of Michigan as an optional component of the similar outpatient network study. 
Chapters three and five both use data from the optional 2014-15 season and the preliminary year 
of HAIVEN, the 2015-16 season. The protocols were the same for both seasons; adults 
hospitalized within the previous three days were enrolled if they had evidence of a respiratory 
symptom (such as cough, sore throat, wheezing etc.) and a constitutional symptom (such as 
fever, myalgia, etc.) with onset in the last ten days. Participants were consented, interviewed, and 
swabbed, and the swabs were tested for influenza. Enrollment interview questions for each 
season are available as Figure 1.2 for the 2014-15 season and Figure 1.3 for the 2015-16 season.  
1.2.4 Influenza Surveillance and Hospital Records in Israel 
As mentioned, many countries are not members of annual VE networks, and therefore do 
not produce VE estimates routinely. Israel is one such country, though they do conduct robust 
sentinel surveillance in which patients with ILI are swabbed at certain primary care offices. 
Previously, these data were used to produce VE estimates against outpatient visits published for 
three seasons; one manuscript covered the 2014-2015 and 2015-2016 seasons, and one covered 
the 2016-2017 season47,48. There are no manuscripts in Israel or the Middle East estimating VE 
against hospitalization. There is no robust sentinel influenza surveillance in the hospital that 
could be used to calculate VE, however, Israel has a detailed medical record system that can be 
utilized to get accurate vaccination information from birth in addition to data on laboratory 
confirmed influenza outcomes. 
 In Israel, there are four major state-mandated health service organizations, the largest of 
which is Clalit Health Services (CHS). CHS provides healthcare for over half of Israelis at 
hospitals and clinics geographically distributed throughout Israel, covering Jewish Israelis, Arab 
Israelis and the Ultra Orthodox. The majority of Israelis stay insured by the same insurer 
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provider throughout their entire lives, meaning that detailed influenza vaccine information can be 
collected through the medical record from birth. In addition, vaccines are not offered at 
pharmacies or other third party locations, save certain school vaccine campaigns which are now 
being reported to insurer/providers after the fact. For this reason the medical record contains a 
complete reports of vaccination history. The availability of a detailed and accurate exposure 
measurement in addition to the lack of data on influenza VE in this region makes Israel an ideal 
location to study VE. In chapter 2, I use data from CHS to estimate influenza VE in hospitalized 
children who are fully vaccinated and ‘partially’ vaccinated (i.e. have only received one 
influenza vaccine). 
1.2.5 Predictors and Prevention of Severe Outcomes During Acute Respiratory Infection 
Related Hospitalization 
During seasonal influenza epidemics, young children are most at risk for influenza 
infection and the elderly (adults 65 years of age and older) are most at risk for severe influenza 
related outcomes. From 1977 until 2009, seasonal influenza epidemics were characterized by 
circulation of seasonal influenza A viruses A(H3N2) and A(H1N1) in addition to influenza B 
viruses.  In April 2009, the rapid emergence of a new influenza A(H1N1) virus was 
characterized by a rise in hospitalizations among previously healthy young adults. This increase 
in severity associated with the A(H1N1)pdm09 strain lead to the declaration of an influenza 
pandemic. Since 2009, the influenza A(H1N1)pdm09 strain has replaced the former seasonal 
A(H1N1) in co-circulation with influenza A(H3N2).  
During the 2009 influenza A(H1N1) pandemic individuals thought to be at low risk for 
severe influenza, such as those under the age of 65 without recognized underlying conditions, 
were hospitalized at a higher than expected rate49. There were also new predictors of severe 
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influenza identified during this pandemic, with morbid obesity being the most consistently 
identified factor50–52. As population level immunity for the A(H1N1)pdm09 increases with 
increased exposure through seasonal infection and vaccination, the epidemiology of this virus 
must be monitored. Since the 2009 pandemic, the age of those hospitalized for influenza 
A(H1N1)pdm09 infection has increased 53–55. Understanding who is most at risk for severe 
influenza is critical, so that they can be targeted for antiviral treatment and vaccination in the 
event of a vaccine-shortage or influenza pandemic.  
There are two main ways to mediate the burden of severe influenza infection; to 
vaccinate to prevent influenza onset among individuals at high risk for severe outcomes, and to 
give antiviral drugs, specifically neuraminidase inhibitors, to individuals who already have 
influenza to reduce severe outcomes. There is some evidence that the influenza vaccine may 
reduce severity as well as incidence of influenza, though the results evaluating this association 
are mixed28,29,56,57. In the past five years there have been two influenza A(H3N2) seasons that 
have been particularly severe; in part due to very low vaccine effectiveness against influenza 
A(H3N2).58,59. Understanding the role of the influenza vaccine in reducing severity in these 
seasons when the vaccine did not succeed in reducing influenza A(H3N2) incidence is critical, 
both for informing messaging in the context of poor VE and for improving current vaccines. 
   There is more extensive evidence linking neuraminidase inhibitors and influenza 
severity reduction. The most commonly used neuraminidase inhibitor is oseltamivir. The CDC 
currently recommends that hospitalized patients be treated with antivirals upon clinical suspicion 
of influenza and that clinicians should not wait for influenza test results before treatment60. 
Despite this recommendation and the relative severity of the 2009 influenza season, treatment 
rates fell in the immediate post-pandemic years, though levels have been increasing since then61. 
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Many studies have indicated that antiviral drugs can reduce influenza symptom length, especially 
when used within two-days of symptom onset62,63. While most studies of antiviral effectiveness 
have focused on the ability of antivirals to shorten and lessen the symptoms of relatively mild 
illness, recently, the ability of antiviral drugs to prevent death among individuals hospitalized 
with influenza has been shown60,64–67. Additionally, numerous studies have reported that 
oseltamivir is most effective when prescribed within two-days of symptom onset which has 
affected prescribing behavior, leading some physicians to not treat patients whose illness onset is 
greater than 48 hours from hospital admission68,69.  There is evidence that while antivirals are 
more effective the closer they are used to illness onset, they are effective at reducing inpatient 
mortality up to five days from symptom onset49,66. Treatment is recommended in individuals at 
high risk of severe influenza irrespective of time from illness onset70. 
Numerous studies annually evaluate influenza VE against hospitalization; harnessing 
these data to understand the effectiveness of antivirals and vaccination at preventing severe 
influenza outcomes is critical. However, using TND data to understand influenza severity in the 
hospital is challenging. While the strength of the TND is its control for health care seeking 
behavior, when these data are used to evaluate severity, this control is no longer present. This is 
particularly a problem if individuals who frequently seek care are older and/or have numerous 
chronic conditions, as both are more likely to present and to be admitted to the hospital with a 
less severe disease. There is no direct way to adjust for this admission bias; variables such as age 
and comorbid conditions can be adjusted for, but it is not possible to directly measure the 
impetus for a physician to admit a patient to the hospital.  
 This problem persists when evaluating the impact of vaccination and antivirals on 
influenza severity. The same factors that are related to vaccine receipt are also likely related the 
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threshold of illness severity that causes a patient to present and be admitted to the hospital, as 
well as some factors that may be related to their likelihood of further deteriorating and having a 
severe outcome. The differential administration of antivirals should not, in theory, be as 
problematic; all individuals hospitalized with suspected or confirmed influenza are 
recommended to be treated as close to illness onset as possible. However, in practice, these 
guidelines may not be followed completely, with patients who present earlier in their illness 
being more likely to be treated or with physician driven testing practices also influencing 
treatment. In addition, antivirals that are given to patients with very severe disease who are far 
along in their disease course may not be effective, therefore, both timing of hospital presentation 
as well as antiviral administration needs to be taken into account.  
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Figure 1.1  Calculation of Influenza Vaccine Effectiveness using the Test Negative Design 
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Figure 1.2 Eligibility Scheme for Enrollment in 2014-2015 US Flu VE Option A Study 
2014-15 Patient Eligibility Scheme 
 
Patient eligibility is determined by examining the chief complaint, admission diagnosis, or hospital problem for a diagnosis of interest (listed 
above). The admission note examined for evidence of onset in the previous 10 days. 
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Figure 1.3 Eligibility Scheme for Enrollment in the 2015-2016 Season of the HAIVEN Study 
2015-16 Patient Eligibility Scheme 
Patients require a respiratory infection syndrome (left box) with onset in previous 10 days or 
respiratory condition with new onset of a symptom of infection (middle box), or a symptom of 
infection with new onset of a respiratory condition symptom (right box) 
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Chapter 2 Influenza Vaccine Effectiveness Against Hospitalization in Fully and 
Partially Vaccinated Children in Israel; 2015-16, 2016-17, and 2017-181 
 
2.1 Author Summary 
There are no estimates of influenza VE against hospitalization in Israel, and very few analyses 
from any country comparing VE in fully and partially vaccinated hospitalized children. In this 
analysis we found that influenza vaccines were effective at preventing influenza A and B related 
hospitalization in fully vaccinated children. Our results support recommendations that Israeli 
children receive two influenza vaccines in their first season of vaccination. 
2.2 Abstract 
Influenza vaccine effectiveness (VE) varies by season, circulating influenza strain, age, and 
geographic location. There have been few studies of influenza VE among hospitalized children, 
particularly in Europe and the Middle East. We estimated VE against influenza hospitalization 
among children six months to eight years at Clalit Health Services hospitals in Israel in the 2015-
16, 2016-17, and 2017-18 influenza seasons using the test-negative design. Estimates were 
computed for full and partial vaccination. We included 326 influenza-positive cases and 2821 
influenza-negative controls (140 cases and 971 controls from 2015-16, 36 cases and 1069 
controls from 2016-17, and 150 cases and 781 controls from 2017-18). Over all seasons, VE was 
53.9% for full vaccination (95% CI:(38.6,68.3)), and 25.6% for partial vaccination (95% CI:(-3, 
                                                
1 Chapter 2 has been published as: Segaloff H.E., Leventer-Roberts M., Riesel D., Malosh R.E., Feldman B. S., 
Shemer-Avni Y., Key C., Monto A.S., Martin E.T., Katz M.A. Influenza Vaccine Effectiveness Against 
Hospitalization in Fully and Partially Vaccinated Children; 2015-16, 2016-17 and 2017-18. Clin Infect Dis. (2019). 
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47)). In 2015-16, most viruses were influenza A(H1N1) and vaccine lineage-mismatched 
influenza B/Victoria; VE for fully vaccinated children was statistically significant for influenza 
A (80.7%, 95% CI:(40.3,96.1)) but not B (23.0%, 95% CI:(-38.5, 59.4)). During 2016-17, 
influenza A(H3N2) predominated, and VE was (70.8%, 95% CI:(17.4, 92.4)). In 2017-18, 
influenza A(H3N2), H1N1 and lineage-mismatched influenza B/Yamagata co-circulated; VE 
was statistically significant for influenza B (63.0% 95% CI: (24.2,83.7)), but not A (46.3%, 95% 
CI:(-7.2, 75.3)). Influenza vaccine was effective in preventing hospitalizations among fully 
vaccinated Israeli children over three influenza seasons, but not among partially vaccinated 
children. There was cross-lineage protection in a season where the vaccine contained B/Victoria 
and the circulating strain was B/Yamagata, but not in a season with the opposite vaccine-
circulating strain distribution. 
2.3 Introduction 
Influenza viruses circulate globally each year and cause substantial morbidity and 
mortality. Young children are at high risk for severe influenza-related outcomes including 
hospitalization and death [1,71–74] Vaccination is the most effective strategy for prevention of 
influenza-related illness and is recommended annually by the Israeli Ministry of Health (MoH) 
and the Advisory Committee on Immunization Practices in the United States for individuals six 
months and older [13,14].  Both recommendations specify that children aged six months through 
eight years receive two doses of influenza vaccine if they have not received more than one 
influenza vaccine previously [14].  
Due to frequent genetic changes among circulating influenza viruses that require regular 
updates to vaccine composition, influenza vaccine effectiveness (VE) is evaluated each year.  
Annual network studies in the United States and Europe have shown substantial variation in VE 
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by circulating influenza virus, season, age, and geographic location [75–77]. However, few studies 
have evaluated influenza VE in preventing hospitalization in children spanning multiple years, 
and evidence is particularly sparse from Europe and the Middle East [34–37].  
In Israel, influenza circulation is seasonal and peaks in the winter. Administration of 
inactivated influenza vaccines is part of covered services in outpatient clinics run by four large, 
national healthcare funds. Two recent studies evaluated influenza VE in preventing medically-
attended influenza in outpatient clinics in Israel [47,48], but VE against hospitalization has not 
been described.  
In this study, we evaluated the VE of trivalent inactivated influenza vaccines (TIV) 
among hospitalized Israeli children insured by Clalit Health Services (CHS), the largest Israeli 
healthcare organization, during the 2015-16, 2016-17, and 2017-18 influenza seasons. For each 
season, we estimated VE for fully and partially vaccinated children using complete vaccine 
receipt history from birth recorded by CHS.  
2.4 Methods 
2.4.1 Study Population and Data Source 
CHS is the largest integrated payer-provider healthcare organization in Israel. It provides 
care to 4.5 million people, over 50% of Israel’s population, and CHS hospitals are located 
throughout the country.  
We included hospitalizations of children aged six months through eight years who were 
tested for influenza as part of clinical care by reverse-transcriptase polymerase chain reaction 
(RT-PCR) during hospitalization at any CHS hospital during the 2015-16, 2016-17 and 2017-18 
influenza seasons. Individuals were excluded if they were not lifetime CHS members, received 
their vaccine <14 days before hospitalization, received the live attenuated influenza vaccine 
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(LAIV) or quadrivalent inactivated vaccine (QIV) in the current influenza season, were 
hospitalized outside of the influenza season, or were tested for influenza >10 days post-hospital 
admission. 
2.4.2 Study Design 
This was a test-negative design study that examined data retrospectively over three influenza 
seasons. We considered the beginning of the season to be the week when the first influenza-
positive sample was reported, and the end of the season to be the week when sentinel 
surveillance ended, based on Israeli MoH Surveillance [78]. The 2015-16 season occurred 
between October 11, 2015 and April 16, 2016, the 2016-17 season between October 8, 2016 and 
April 16, 2017. For the 2017-18 season we included hospitalizations from October 21, 2017 
through March 18 2018, the latest date that data were available at the time of analysis, and three 
weeks before the end of the influenza season. 
2.4.3 Outcome and Vaccination Status 
Influenza cases were individuals who tested positive for influenza by RT-PCR during a 
hospital admission. Vaccinated individuals were those who had received TIV from September 1st 
of the influenza season of interest ≥14 days before hospital admission.  
Fully vaccinated individuals were those who had received a current season vaccine (TIV 
only) and had received ≥2 influenza vaccines previously, or had received two current season 
vaccines ≥14 days apart. Partially vaccinated individuals were those who had received a current 
season vaccine and did not meet the criteria for full vaccination [14,79]. Children with no 
electronic health record (EHR) evidence of receiving the current season vaccine were considered 
unvaccinated. 
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2.4.4 Covariates 
Demographic covariates included age at hospitalization, sex, and ethnicity. Ethnicity was 
defined at the clinic catchment level as predominantly Jewish or Arab. Clinical covariates 
included comorbid conditions, number of hospitalizations in the prior year, time from hospital 
admission to RT-PCR test, and number of weeks from hospital admission to the peak of the 
influenza season. Comorbid conditions were defined for the two years before hospitalization 
using ICD-9 discharge codes previously described [80,81] (Table 2.1). Time from hospital 
admission to season peak, determined from Israeli MoH surveillance, was divided into two-week 
intervals and included a maximum of ten two-week intervals per season because data were sparse 
beyond this point [78]. All variables were extracted from CHS’s integrated clinical and 
administrative EHR.  
2.4.5 Statistical Analysis 
We compared demographic and clinical characteristics between influenza-positive and 
influenza-negative children, using chi-square or Fisher’s exact tests for categorical variables and 
Wilcoxon Rank-Sum test for continuous variables. 
We used Firth’s corrected logistic regression to estimate the adjusted odds ratio (aOR) for 
vaccination, comparing those who tested positive for influenza to those who tested negative [82]. 
VE was calculated separately for fully and partially vaccinated children as 1-(aOR) x 100. VE 
was computed for each season separately and for all seasons combined, for two age groups 
(children <2 and children aged ≥2) and for children with at least one comorbidity. Adjusted 
models included admission hospital (hospital A vs. others), log-transformed age at 
hospitalization in months, presence of any comorbidity, number of hospitalizations in the past 
year, days from hospital admission to RT-PCR test. In order to adjust for confounding caused by 
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variations in influenza positivity and cumulative vaccination rates throughout each season across 
the three seasons, number of weeks between hospital admission and peak of the influenza season 
were also included in adjusted models, as described in previous VE studies [83]. For VE 
estimates pooled across seasons, influenza season of hospitalization was a covariate. VE 
estimates were calculated for influenza A and B separately and were considered statistically 
significant if the 95% confidence interval did not include zero. As influenza B did not circulate 
in 2016-17, pooled season estimates of influenza B did not include data from the 2016-17 
season. All analysis was completed using R Studio. The logistf package was used to compute 
Firth’s corrected models. 
2.4.6 Sensitivity Analysis 
We included all qualifying hospitalizations in our primary analysis. We also performed a 
sensitivity analysis including only the first hospitalization for each individual in each season. 
During 2016-17, children in second grade received influenza vaccine in school, but records of 
these vaccinations were not routinely entered into the CHS EMR. To evaluate the impact of these 
potentially incomplete vaccination records, we conducted two additional analyses; we removed 
2016-17 data from the overall VE estimate, and we estimated influenza VE in the 2016-17 
excluding individuals >5 years old as of September 1, 2016.  
2.4.7 Ethics Approval 
The CHS research ethics committee approved this de-identified, medical-record based study. 
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2.5 Results 
2.5.1 Participant Characteristics 
We identified 3,746 hospitalizations of children who were tested for influenza by RT-PCR 
in six CHS hospitals over three influenza seasons. After exclusions, 3,147 hospitalizations 
remained in the sample (Figure 2.1). The majority of these hospitalizations were in children who 
were male (55.2%), six months to < 2 years old (60.7%), and had at least one comorbid condition 
(54.3%).  
Over all three seasons, 326 of 3,147 hospitalizations (10.4%) included a positive influenza 
test (Table 1); In the 2015-16 season there were 140 influenza-positive specimens; 45 (32%) 
influenza A and 95 (68%) influenza B (Figure 2.2 A). The 2016-17 season had few positives 
(N=36), all of which were influenza A (Figure 2.2 B). In 2017-18 there were 150 positive 
specimens; 71 (47%) influenza A and 79 (53%) influenza B (Figure 2.2 C). The mean time from 
admission to RT-PCR test was 1.5 days, 99% of children were tested within 7 days of admission 
and 96% were tested within 4 days (data not shown). 
Only 7.7% of hospitalized children under 2 years old tested positive for influenza 
compared to 13.3% of children aged 2-4, and 16.7% of children aged 5-8 (p<.0001) . Children 
with at least one comorbid condition, and with more than one hospitalization in the year prior to 
admission were less likely to be influenza-positive  (Table 2.2).   
Overall, 504 (16.0%) hospitalizations were among fully vaccinated children, 575 (18.3%) 
were among partially vaccinated children, and 2068 (65.7%) were among unvaccinated children. 
Frequency of partial vaccination was highest in children under 2 years old (22.8%). (Table 2.3). 
Children with at least one comorbid condition and children with more than one hospitalization in 
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the prior year were more likely to be vaccinated compared to those with no comorbid conditions 
and those who had one or zero hospitalizations in the previous years, respectively (Table 2.3). 
2.5.2 Vaccine Effectiveness Estimates 
Influenza VE pooled over the three seasons was 53.9% (95% CI: 38.6%, 68.3%) for fully 
vaccinated children; TIV was effective against influenza A (63.9%, 95% CI: 38.7%, 80.1%) and 
influenza B (42.3%, 95% CI: 8.6%, 64.9%) in fully vaccinated children. Pooled VE for partial 
vaccination was 25.6% (95% CI: -3.0%, 47.0%). Partial vaccination was effective against 
influenza A (45.1%, 95% CI: 12.3%, 67.1%), but not against influenza B (4.1%, 95% CI: -
45.4%, 38.1%) (Table 2.4).  
 Influenza vaccine was effective in preventing hospitalizations in each of the three seasons 
among fully vaccinated children; VE was 45.8% (95%CI: 7.2%, 69.9%) in 2015-16, 70.8% in 
2016-17 (95%CI: 17.4%, 92.4%) and 56.5% (95% CI: 25.5%, 75.7%) in 2017-18 (Table 2.4). 
VE was consistently lower for partial vaccination compared to full vaccination, and none of the 
season-specific estimates were statistically significant.  
 VE against influenza A was 80.7% in the 2015-16 season (95% CI: 40.3%, 96.1%) but 
was lower and not significant in the 2017-18 season (46.3%, 95% CI: -7.2%, 75.3%). 
Conversely, VE against influenza B was only 23.0% (95% CI: -38.5%, 59.4%) in 2015-16 but 
was 63.0% in 2017-18 (95% CI: 24.2%, 83.7%).  
 Overall VE did not vary by age; VE was 48.1% among individuals under 2 years old, and 
49.6% among children 2 -8 years old. Compared to children 2-8 years old, VE point estimates 
for children under 2 were higher against influenza A and lower against influenza B, but CIs 
overlapped for both comparisons. Adjusted Influenza VE for fully vaccinated children with at 
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least one comorbidity was 35.8%,  (95% CIs 0.8, 59.5), which did not vary significantly from the 
overall VE estimate (Table 2.5). 
When analyses were restricted to the first hospitalization per individual in each influenza 
season, VE did not significantly change (Table 2.6). Results were similar in additional analyses 
removing individuals affected by the in-school vaccination program in 2016-17 (Table 2.7).  
2.6 Discussion 
Our study, the first to evaluate influenza VE against hospitalization in Israel, found that 
influenza vaccine was effective in preventing hospitalization associated with laboratory-
confirmed influenza in fully vaccinated children aged six months to eight years across three 
influenza seasons. Influenza vaccine was effective in each season, although the degree of 
effectiveness varied. Among fully vaccinated children, the vaccine was effective against 
influenza A in two of three seasons, and influenza B in 2017-18. Estimated VE for partial 
vaccination was consistently lower than VE for full vaccination. These findings reinforce current 
recommendations in Israel and many other countries to immunize young children with influenza 
vaccine annually and to give vaccine-naïve children two influenza vaccines [13,14]. They also 
demonstrate that the vaccine is effective at reducing the risk for the most severe complications of 
influenza.  
Due to a mismatch in circulating and vaccine-contained influenza B lineage in 2015-16 
and 2017-18, we were able to approximate the degree of cross-lineage protection conferred by 
TIV in both seasons. In 2017-18, according to surveillance data from the Israeli MoH, over 95% 
of influenza B viruses were of the Yamagata lineage [unpublished data, Israel Centers for 
Disease Control]. We found that TIV, which contained influenza B/Victoria viruses in 2017-18, 
was 63% effective at reducing influenza-related hospitalizations despite this mismatch. 
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Interestingly, we did not find evidence for cross-lineage protection in the 2015-16 season, when 
the vaccine contained the B/Phuket-like (Yamagata lineage) virus but 95% of the circulating 
influenza B was of the Victoria lineage [84], and VE against influenza B was low (23%).  
 Our finding of significant cross-lineage protection against influenza B in 2017-18 was 
also seen in Canada, where circulating influenza B was nearly exclusively B/Yamagata and the 
vaccine contained B/Victoria. In 2017-2018, approximately 70% of vaccine used in Canada was 
TIV, and VE against outpatient influenza B was 55% [85]. In Australia, where QIV was used 
exclusively and B/Yamagata also predominated, VE against influenza B was 57% [86].  The 
similar VE estimates against influenza B in our study in Israel, along with estimates from Canada 
and Australia, suggest that QIV did not confer additional protection beyond that provided by TIV 
in the 2017-2018 season, despite the lineage mismatch. 
The lack of influenza B cross-lineage protection that we observed in the 2015-16 season 
is consistent with VE findings among children from outpatient studies in Finland, in a multisite 
study in Europe and an outpatient study in Israel in the same year [47,87,88]. In all three settings, 
the same mismatch occurred between the vaccine (Yamagata) and circulating (Victoria) 
influenza B lineages, and TIV was not effective against influenza B.  In contrast, in Canada, 
where approximately 85% of the vaccines distributed were TIV, VE was 54% against influenza 
B/Victoria [89].  
Our high VE estimates for influenza A in 2015-16 and 2016-17 were similar to results 
described in other populations. We found a VE of 81% against influenza A in 2015-16,when 
virtually all circulating influenza in Israel was influenza A(H1N1)pdm [90].  This was similar to 
estimates of TIV effectiveness against influenza A among young Finnish children (78%) in the 
same year [88]. Studies in Canada and the US also demonstrated significant VE against influenza 
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A(H1N1)pdm in children in 2015-2016 [59,89,91]. In contrast, a study in outpatient clinics in Israel 
estimated a VE of -8% against influenza A among children <17 years old [48]. Notably, the low 
VE in the Israeli study occurred in a broader age group and at a different level of care (outpatient 
setting) compared to our study. In 2016-17, our VE estimate against influenza A (71%) was 
consistent with estimates against influenza A in an Israeli outpatient study among children aged 
5-17 (69%), but much higher than estimates for children aged 6 months to 4 years in the same 
study (39%) [48].  The US Flu VE network also found significant VE against influenza A in 
2016-2017 in children <8 years old [32]. In 2017-18, we estimated a VE of 46% against influenza 
A, which was consistent with interim estimates of VE against influenza A/H3N2 in children <8 
years old in the US but higher than interim estimates from Australia in children <17 years old 
[86,92]. 
While the vaccine was effective among fully vaccinated children, estimated VE was 
consistently lower among partially vaccinated children, though confidence intervals overlapped. 
This discrepancy between full and partial vaccination has been demonstrated in previous studies 
[39–42]. In our study, children aged 6 months to 2 years were much more likely than older children 
to be partially vaccinated. Concerns exist about lower influenza VE in young children [93].  In 
our study, however, VE among children < 2 years old was very similar to VE in children 2-8 
years old. 
Our study has limitations. We relied on a retrospective analysis based on clinical testing, 
rather than an acute respiratory infection (ARI) inclusion criterion. This approach could have led 
to rates of influenza positivity that are different compared to other influenza VE studies that used 
specific case definitions such as ARI, and could have introduced potential bias to our influenza 
VE estimates. In addition, we could not confirm the date of illness onset prior to admission.  We 
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may have included individuals who had been ill for long periods of time before hospital 
admission. Delayed hospital presentation could increase the likelihood of false-negative RT-PCR 
results if the infection has cleared before testing [94]. We would expect this bias to be non-
differentially associated with vaccination status, likely biasing our VE results to the null and 
leading to an underestimation of VE. In order to reduce inclusion of false-negatives, we excluded 
individuals who were tested more than ten days after hospital admission. We included 
individuals tested up to 10 days before admission because previous studies suggest that children 
may shed influenza for a long period of time, with a substantial decrease in shedding after 10 
days [94–96]. Although this strategy could still allow inclusion of initially infected individuals who 
had ceased shedding virus, nearly all children were tested within 4 days, suggesting that the 
inclusion of individuals far from illness onset was likely minimal. Clinical test results did not 
include subtype or lineage information, leaving us unable to make subtype or lineage specific 
estimates. However, the subtyping results from annual surveillance from the Israeli MoH 
allowed us to make inferences about the relative frequency of subtype and lineage specific 
influenza infections in our study. In addition, while CHS serves over 50% of the Israeli 
population, representing a geographically and socioeconomically diverse group, the exact 
representativeness of CHS members to the population of Israel is not known, and our results may 
not be generalizable to the entire Israeli population. Finally, recent interest in the impact of 
previous year vaccination on current season VE has grown, and many studies now consider 
repeat vaccination when reporting VE [97,98]. Unfortunately, our small sample size prevented us 
from evaluating the impact of sequential vaccination on VE. A future, larger study in this 
population addressing the impact of repeat vaccination would benefit from the detailed life 
course vaccination history available for CHS members. 
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In conclusion, we found influenza vaccine to be effective against hospitalization for 
laboratory-confirmed influenza in fully vaccinated children aged six months to eight years in 
Israel from 2015-2018. The VE for partial vaccination was consistently lower than for full 
vaccination. There was also high VE against influenza A in 2015-16 and 2016-17, and influenza 
B in 2017-18. We found evidence for cross-lineage protection from vaccination when TIV 
included B/Victoria but not when TIV included B/Yamagata, though these estimates rely on 
small sample sizes and have wide confidence intervals. Our findings suggesting that influenza 
VE reduces the risk for severe disease in children further strengthen current recommendations 
for annual influenza vaccine in children. The higher VE for children who were fully vaccinated 
is consistent with current guidelines that recommend two vaccines for vaccine -naïve children 
through age eight.   
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Table 2.1 ICD9 Codes Used to Define Comorbidity Categories 
Categories Subcategories ICD 9 Codes 
Neuromuscular Brain and spinal cord malformations 740.0-742.9 
 Mental retardation 318.0-318.2 
 Central nervous system degeneration and 
disease 
330.0-330.9, 334.0-334.2, 335.0-335.9 
 Infantile cerebral palsy 343.0-343.9 
 Muscular dystrophies and myopathies 359.0-359.3 
Cardiovascular Heart and great vessel malformations 745.0-747.4 
 Cardiomyopathies 425.0-425.4, 429.1 
 Conduction disorders 426.0-427.4 
 Dysrhythmias 427.6-427.9 
Respiratory Respiratory malformations 748.0-748.9 
 Chronic respiratory disease 770.7 
 Cystic fibrosis 277.0 
Renal Congenital anomalies 753.0-753.9 
 Chronic renal failure 585 
Gastrointestinal Congenital anomalies 750.3, 751.1-751.3, 751.6-751.9 
 Chronic liver disease and cirrhosis 571.4-571.9 
 Inflammatory bowel disease 555.0-556.9 
Hematologic or 
Immunologic  
Sickle cell disease 282.5-282.6 
 Hereditary anemias 282.0-282.4 
 Hereditary immunodeficiency 279.0-279.9, 288.1-288.2, 446.1 
 Acquired immunodeficiency 0420-0421 
Metabolic Amino acid metabolism 270.0-270.9 
 Carbohydrate metabolism 271.0-271.9 
 Lipid metabolism 272.0-272.9 
 Storage disorders 277.3, 277.5 
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 Other metabolic disorders 275.0-275.3, 277.2, 277.4, 277.6, 277.8-
277.9 
Other congenital or 
genetic defect 
Chromosomal anomalies 758.0-758.9 
 Bone and joint anomalies 259.4, 737.3, 756.0-756.5 
 Diaphragm and abdominal wall 553.3, 756.6-756.7 
 Other congenital anomalies 759.7-759.9 
Malignancy Malignant Neoplasms 140.0-208.9, 235.0-239.9 
Asthma  519.1, 493.0-493.9 
Codes and categories taken from Feudtner et al [79]. and Martin et al  [80]. 
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Figure 2.1 Flow Chart of Inclusion of Hospitalizations of Patients at Clalit Health Services 
Hospitals Tested for Influenza by RT-PCR During the 2015-16, 2016-17, and 2017-18 Influenza 
Seasons. 
 
 
 
Indeterminate vacation status refers to a vaccination received 1 to 13 days before hospital 
admission, or two vaccinations received less than 14 days apart in the same season for an 
individual who was previously vaccine naïve. 
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Figure 2.2 Number of Influenza-Positive Samples from Children Hospitalized at Clalit Health 
Services Hospitals and Tested for Influenza by RT-PCR by Week of Hopsitalization 
 
 
 
Each panel represents a different influenza season, A is the 2015-16 season, B is the 2016-17 
season and C is the 2017-18 season. Shades of gray indicate PCR results; the darkest gray 
indicates the number of Influenza-A positive specimens, the medium gray indicates influenza B, 
and the lightest gray indicates the number of influenza-negative specimens. 
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Table 2.2 Descriptive Characteristics of Hospitalizations of Children Aged Six Months Through 
Eight Years Tested for Influenza by RT-PCR, by Influenza Status 
Characteristics,	n	(Column	%)	 Total	(n=3147)	 Influenza	Positive	
(n=326)	
Influenza	Negative	
(n=2821)	
Pa	
Season	 	 	 	 <.0001	
			2015-2016	 1111	(35.3%)	 140	(42.9%)	 971	(34.4%)	 	
			2016-2017	 1105	(35.1%)	 36	(11.0%)	 1069(37.9%)	 	
			2017-2018	 931	(29.6%)	 150	(46.0%)	 781	(27.7%)	 	
Male	 1736	(55.2%)	 185	(56.7%)	 1551	(55.0%)	 0.54	
Admission	Hospital	 	 	 	 <.0001	
			Hospital	A	 1407	(44.7%)	 123	(37.7%)	 1284	(45.5%)	 	
			Hospital	B	 133	(4.2%)	 25	(7.7%)	 108	(3.8%)	 	
			Hospital	C	 90	(2.9%)	 15	(4.6%)	 75	(2.7%)	 	
			Hospital	D	 856	(27.2%)	 94	(28.8%)	 762	(27.0%)	 	
			Hospital	E	 369	(11.7%)	 50	(15.3%)	 319	(11.3%)	 	
			Hospital	F	 292	(9.3%)	 19	(5.8%)	 273	(9.7%)	 	
Age	on	September	1st	 	 	 	 <.0001	
			6	months	to	<2	years	 1910	(60.7%)	 147	(45.1%)	 1763	(62.5%)	 	
			2	years	to	<	5	years	 805	(25.6%)	 107	(32.8%)	 698	(24.7%)	 	
			5	years	to	<9	years	 432	(13.7%)	 72	(22.1%)	 360	(12.8%)	 	
Ethnicity		 	 	 	 0.72	
				Arab	 1158	(36.8%)	 117	(35.9%)	 1041	(36.9%)	 	
			Jewish	 1989	(63.2%)	 209	(64.1%)	 1780	(63.1%)	 	
Underlying	Chronic	Condition		 	 	 	 	
					Any	 1709	(54.3%)	 158	(48.5%)	 1551	(55.0%)	 0.02	
					Asthma	 563	(17.9%)	 60	(18.4%)	 503	(17.8%)	 0.8	
					Neuromuscular	 335	(10.6%)	 32	(9.8%)	 303	(10.7%)	 0.61	
					Cardiac	 417	(13.3%)	 34	(10.4%)	 383	(13.6%)	 0.11	
					Respiratory	 142	(4.5%)	 6	(1.8%)	 136	(4.8%)	 0.01	
					Renal	 59	(1.9%)	 3	(0.9%)	 56	(2.0%)	 0.18	
					Gastrointestinal	 84	(2.7%)	 5	(1.5%)	 79	(2.8%)	 0.18	
					Hematologic	 195	(6.2%)	 22	(6.7%)	 173	(6.1%)	 0.66	
					Metabolic	 183	(5.8%)	 19	(5.8%)	 164	(5.8%)	 0.99	
					Genetic	 254	(8.1%)	 22	(6.7%)	 232	(8.2%)	 0.35	
					Malignancies	 474	(15.1%)	 34	(10.4%)	 440	(15.6%)	 0.01	
Vaccination	Status	 	 	 	 0.04	
				Unvaccinated	 2068	(65.7%)	 234	(71.8%)	 1834	(65.0%)	 	
				Partially	Vaccinated	 575	(18.3%)	 53	(16.3%)	 522	(18.5%)	 	
				Fully	Vaccinated	 504	(16.0%)	 39(12.0%)	 465(16.5%)	 	
Number	of	Hospitalizations	in	
Prior	Year	
														 	 	 <.01	
			0	 1934	(61.5%)	 224	(68.7%)	 1710	(60.6%)	 	
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			1	 458	(14.6%)	 45	(13.8%)	 413	(14.6%)	 	
			>1	 755	(24.0%)	 57	(17.5%)	 698	(24.7%)	 	
Length	of	Stay	(mean,	std)	 5.1	days	(6.4)	 4.8	days	(7.4)	 5.1	days	(6.3)	 0.15	
Days	from	Admission	to	PCR	
testing	(mean,	std)	
1.53	days	(1.3)	 1.48	days	(1.26)	 1.53	days	(1.3)	 0.59	
a. P	Values	are	calculated	byMcNemar’s	Chi	Square	tests	or	Fisher’s	exact	tests	for	categorical	
variables	and	Wilcoxon’s	Rank	Sum	tests	for	continuous	variables	
Abbreviations:	RT-PCR:	Reverse	Transcriptase	PCR	
std:	standard	deviation	
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Table 2.3		Descriptive Characteristics of Hospitalizations of Children Aged Six Months Through 
Eight Years Tested for Influenza by RT-PCR by Vaccination Status 
Characteristics,	N	
(Column%)	
Total	
(N=3147)	
Fully	Vaccinateda	
(N=	504)	
Partially	Vaccinated	
(N=575)	
Not	Vaccinated	
(N=2068)	
Pb	
Season	 	 	 	 	 <.01	
			2015-2016	 1111	(35.3%)	 173	(34.3%)	 209	(36.3%)	 729	(35.2%)	 	
			2016-2017	 1105	(35.1%)	 171	(33.9%)	 169	(29.4%)	 765	(37.0%)	 	
			2017-2018	 931	(29.6%)	 160	(31.7%)	 197	(34.3%)	 574	(27.8%)	 	
Male	 1736	(55.2%)	 288	(16.6%)	 329	(18.9%)	 1119	(64.5%)	 0.26	
Admission	Hospital	 	 	 	 	 <.0001	
			Hospital	A	 1407	(44.7%)	 158	(31.3%)	 238	(41.4%)	 1011	(48.9%)	 	
			Hospital	B	 133	(4.2%)	 27	(5.4%)	 10	(1.7%)	 96	(4.6%)	 	
			Hospital	C	 90	(2.9%)	 21	(4.2%)	 20	(3.5%)	 49	(2.4%)	 	
			Hospital	D	 856	(27.2%)	 170	(33.7%)	 164	(28.5%)	 522	(25.2%)	 	
			Hospital	E	 369	(11.7%)	 58	(11.5%)	 80	(13.9%)	 231	(11.2%)	 	
			Hospital	F	 292	(9.3%)	 70	(13.9%)	 63	(11.0%)	 159	(7.7%)	 	
Age	at	September	
1st	
	 	 	 	 <.0001	
			6	months	to	<2	
years	
1910	(60.7%)	 246	(48.8%)	 436	(75.8%)	 1228	(59.4%)	 	
			2	years	to	<5	years	 805	(25.6%)	 140	(27.8%)	 103	(17.9%)	 562	(27.2%)	 	
			5	years	to	<9	years	 432		(13.7%)	 118	(23.4%)	 36	(6.3%)	 278	(13.4%)	 	
Ethnicity	 	 	 	 	 0.07	
			Arab	 1158	(36.8%)	 199	(39.5%)	 228	(39.7%)	 731	(35.3%)	 	
			Jewish	 1989	(63.2%)	 305	(60.5%)	 347	(60.3%)	 1337(64.7%)	 	
Underlying	Chronic	
Condition	
	 	 	 	 	
			Any	 1709	(54.3%)	 349	(69.2%)	 328	(57.0%)	 1032	(49.9%)	 <.0001	
			Asthma	 563		(17.9%)	 129	(25.6%)	 108	(18.8%)	 326	(15.8%)	 <.0001	
			Neuromuscular	 335	(10.6%)	 91	(18.1%)	 62	(10.8%)	 182	(8.8%)	 <.0001	
			Cardiac	 417	(13.2%)	 92	(18.2%)	 95	(16.5%)	 230	(11.1%)	 <.0001	
			Respiratory	 142	(4.5%)	 39	(7.7%)	 40	(7.0%)	 63	(3.0%)	 <.0001	
			Renal	 59	(1.9%)	 19	(3.8%)	 13	(2.3%)	 27	(1.3%)	 <0.001	
			Gastrointestinal	 84	(2.7%)	 13	(2.6%)	 18	(3.1%)	 53	(2.6%)	 0.75	
			Hematologic	 195	(6.2%)	 32	(6.3%)	 33	(5.7%)	 130	(6.3%)	 0.88	
			Metabolic	 183	(5.8%)	 24	(4.8%)	 37	(6.4%)	 122	(5.9%)	 0.48	
			Genetic	 254	(8.1%)	 78	(15.5%)	 56	(9.7%)	 120	(5.8%)	 <.0001	
			Malignancies	 474	(15.1%)	 94	(18.7%)	 67	(11.6%)	 313	(15.1%)	 <.01	
Influenza	Status	 	 	 	 	 0.06	
			Influenza	A	 152	(4.8%)	 15	(3.0%)	 21	(3.6%)	 116	(5.6%)	 	
			Influenza	B	 174	(5.5%)	 24	(4.8%)	 32	(5.6%)	 118	(5.7%)	 	
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			Influenza	Negative	 2821	(89.6%)	 465	(92.3%)	 522	(90.8%)	 1834	(88.7%)	 	
Number	of	
Hospitalizations	in	
Prior	Year	
	 	 	 	 <.0001	
			0	 1934	(61.5%)	 257	(51.0%)	 331	(57.6%)	 1346	(65.1%)	 	
			1	 458	(14.5%)	 84	(16.7%)	 85	(14.8%)	 289	(14.0%)	 	
			>1	 755	(24.0%)	 163	(32.3%)	 159	(27.6%)	 433	(20.9%)	 	
Length	of	Stay	
(mean,	std)	
5.1	days	(6.4)	 5.3	days	(6.7)	 5.1	days	(6.1)	 5.0	days	(6.4)	 .36	
Admission	to	PCR	
testing	(mean,	std)	
1.5	days	(1.3)	 1.5	days	(1.3)	 1.6	days	(1.4)	 1.5	days	(1.2)	 0.53	
a. Individuals	were	considered	fully	vaccinated	if	they	received	two	current	season	vaccinations	at	least	
14	days	apart	at	least	28	days	before	their	hospital	admission	or	if	they	received	>1	vaccine	before	the	
current	season	and	a	current	season	vaccine	28	days	before	hospitalization.	Individuals	were	
considered	partially	vaccinated	if	they	did	not	meet	the	above	categories	but	did	receive	a	current	
season	vaccine	28	days	before	admission.		
b. P	Values	were	calculated	using	McNemar’s	Chi	Square	tests	or	Fisher’s	exact	tests	for	categorical	
variables	and	Wilcoxon’s	Rank	Sum	tests	for	continuous	variables	
Abbreviations:	RT-PCR:	Reverse	Transcriptase	PCR	
std:	standard	deviation	
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Table 2.4 Percentage of Fully and Partially Vaccinated Children and Adjusted Influenza 
Vaccine Effectiveness Estimates by Season and Influenza Type 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 No. Positive/ No. Evaluated (%) Adjusted VE (95% CI) 
 Fully 
Vaccinated 
Partially 
Vaccinated 
Unvaccinated Fully 
Vaccinated 
Partially 
Vaccinated 
All Seasons      
     All Influenza 39/504 (7.7%) 53/575 (9.2%) 234/2016 (11.3%) 53.9 (38.6, 68.3) 25.6 (-3.0, 47.0) 
     Influenza A 15/480 (3.1%) 21/543 (3.9%) 116/1950 (5.9%) 63.9 (38.7, 80.1) 45.1 (12.3, 67.1) 
     Influenza B* 24/321 (7.5%) 32/389 (8.2%) 118/1216 (9.7%) 42.3 (8.6, 64.9) 4.1 (-45.4, 38.1) 
2015-2016      
     All Influenza 17/173 (9.8%) 24/209 (11.5%) 99/729 (13.6%) 45.8 (7.2, 69.9) 14.1 (-38.9, 48.5) 
     Influenza A 2/158 (1.3%) 6/191 (3.1%) 37/667 (5.5%) 80.7 (40.3, 96.1) 47.7 (-18.3, 80.1) 
     Influenza B 15/171 (8.8%) 18/203 (8.9%) 62/692 (9.0%) 23.0 (-38.5, 59.4) -13.6 (-97.4, 37.2) 
2016-2017      
     All Influenza 3/171 (1.8%) 4/169 (2.4%) 29/765 (3.8%) 70.8 (17.4, 92.4) 30.1 (-79.6, 78.3) 
      Influenza A 3/171 (1.8%) 4/169 (2.4%) 29/765 (3.8%) 70.8 (17.4, 92.4) 30.1 (-79.6, 78.3) 
      Influenza B - - - - - 
2017-2018      
     All Influenza 19/160(11.9%) 25/197 (12.7%) 106/574 (18.5%) 56.5 (25.5, 75.7) 25.9 (-21.1, 55.8) 
      Influenza A 10/151 (6.6%) 11/183 (6.0%) 50/518 (9.7%) 46.3 (-7.2, 75.3) 28.9 (-39.4, 66.2) 
      Influenza B 9/150 (6.0%) 14/186 (7.5%) 56/524 (10.7%) 63.0 (24.2, 83.7) 23.2 (-43.1, 60.8) 
Models were adjusted for log-adjusted age in months, hospital (Hospital A vs others), presence of any comorbidity, prior 
year hospital admission (yes/no), distance of hospital admission from the influenza season peak (in two-week intervals), 
days from admission date to influenza PCR.  Season is included in pooled models. 
Individuals	were	considered	fully	vaccinated	if	they	received	two	current	season	vaccinations	at	least	14	days	apart	at	least	
28	days	before	their	hospital	admission	or	if	they	received	>1	vaccine	before	the	current	season	and	a	current	season	
vaccine	28	days	before	hospitalization.	Individuals	were	considered	partially	vaccinated	if	they	did	not	meet	the	above	
categories	but	did	receive	a	current	season	vaccine	28	days	before	admission.	
Influenza	B	estimates	do	not	include	information	from	2016-17	when	influenza	B	was	not	circulating		
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Table 2.5 Adjusted Influenza Vaccine Effectiveness Estimates by Season and Influenza Type 
Stratified by Age (<2 years old vs. 2-8 years old) and for Children with at Least One 
Comorbidity, Israel, 2015-2018 
 No. Positive/ No. Evaluated (%) Adjusted VE (95% CI) 
 Fully 
Vaccinated 
Partially 
Vaccinated 
Unvaccinated Fully Vaccinated Partially 
Vaccinated 
All Seasons- Any 
Influenza 
     
     Age <2 13/246 (5.3%) 34/436 (7.8%) 100/1228 (8.1%) 48.1 (8.3, 72.6) 9.3 (-27.1, 40.9) 
     Age 2-8 26/258 (10.1%) 19/139 (13.7%) 134/840 (16.0%) 49.6 (20.2, 69.2) 15.8 (-40.4, 51.7) 
     Any Comorbidity 30/349 (8.6%) 30/328 (9.1%) 98/1032 (9.5%) 35.8 (0.8, 59.5) -2.4 (-58.0, 35.1) 
All Seasons- Flu A      
     Age <2 4/237 (1.7%) 15/417 (3.6%) 63/1191 (5.3%) 73.1 (35.4, 91.3) 31.9 (-18.7, 63.1) 
     Age 2-8 11/243 (4.5%) 6/126 (4.8%) 53/759 (7.0%) 49.7 (1.1, 76.3) 32.5 (-117.2, 74.0) 
     Any Comorbidity 13/332 (3.9%) 13/311 (4.2%) 50/984 (5.1%) 43.3 (-4.5, 71.2) 14.1 (-57.5, 56.0) 
All Seasons- Flu B*      
     Age <2 9/242 (3.7%) 19/421 (4.5%) 37/1165 (3.2%) 10.4 (-100.0, 
55.4) 
-32.2 (-131.2, 26.6) 
     Age 2-8 15/247 (6.1%) 13/133 (9.8%) 81/787 (10.3%) 50.4 (12.2, 73.5) -.05 (-81.4, 48.4) 
     Any Comorbidity 17/336 (5.1%) 17/315 (5.4%) 48/982 (4.9%) 26.8 (-28.8, 60.2) -27.9 (-124.7, 30.1) 
2015-2016      
     Age <2 8/93 (8.6%) 11/139 (7.9%) 47/409 (11.5%) 46.4 (-14.6, 77.4) 32.6 (-34.6, 68.5) 
     Age 2-8 9/80 (11.3%) 13/70 (18.6%) 52/320 (16.3%) 44.2 (-17.6, 75.8) -28.2 (-152.4, 37.9) 
      Any 
Comorbidity 
11/114 (9.6%) 14/120 (11.7%) 42/381 (11.0%) 39.4 (-21.9, 72.1) -11.6 (-112.8, 44.1) 
2016-2017      
     Age <2 1/75 (1.3%) 3/129 (2.3%) 14/468 (3.0%) 47.1 (-127.7, 
94.3) 
-7.1 (-234.7, 73.3) 
     Age 2-8 2/96 (2.1%) 1/40 (2.5%) 15/297 (5.1%) 71.7 (-5.6, 94.9) 39.6 (-189.4, 93.8) 
     Any Comorbidity 3/125 (2.4%) 3/106 (2.8%) 12/388 (3.4%) 46.5 (-74.2, 87.2) -20.6 (-302.5, 71.1) 
2017-2018      
     Age <2 4/78 (5.1%) 20/168 (11.9%) 39/351 (11.1%) 64.5 (5.3, 89.3) 4.5 (-74.7, 49.2) 
     Age 2-8 15/82 (18.3%) 5/29 (17.2%) 67/223 (30.0%) 51.3 (4.5, 76.5) 63.7 (1.8, 89.1) 
     Any Comorbidity 16/110 (14.5%) 13/102 (12.7%) 43/263 (16.3%) 35.1 (-24.9, 67.7) 21.2 (-58.4, 62.6) 
Models were adjusted for log-adjusted age in months, hospital (Hospital A vs others), presence of any comorbidity, prior 
year hospital admission (yes/no), distance of hospital admission from the influenza season peak (in two-week intervals), 
days from admission date to influenza PCR.  Season is included in pooled models. 
Individuals were considered fully vaccinated if they received two current season vaccinations at least 14 days apart at least 
28 days before their hospital admission or if they received >1 vaccine before the current season and a current season 
vaccine 28 days before hospitalization. Individuals were considered partially vaccinated if they did not meet the above 
categories but did receive a current season vaccine 28 days before admission. 
Influenza B estimates do not include information from 2016-17 when influenza B was not circulating  
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Table 2.6 Percentage of Fully and Partially Vaccinated and Adjusted Influenza Vaccine 
Effectiveness Estimates by Season and Influenza Type Restricting to First Hospitalization for 
Each Patient 
 
No. Positive/ No. Evaluated (%) Adjusted VE (95% CI) 
 
Fully 
Vaccinated 
Partially 
Vaccinated Unvaccinated Fully Vaccinated Partially Vaccinated 
All Seasons      
     All Influenza 32/432 (7.4%) 51/511 (10.0%) 218/1834 (11.9%) 58.8 (38.9, 73.1) 26.0 (-3.5,47.9) 
     Influenza A 12/412 (2.9%) 20/480 (4.2%) 103/1719 (6.0%) 65.9 (39.2, 82.4) 42.7 (7.1, 66.2) 
     Influenza B* 20/278 (7.2%) 31/351 (8.8%) 115/1088 (10.6%) 50.4 (18.8, 71.0) 0.9 (-39.4,  41.9) 
2015-2016      
     All Influenza 14/152 (9.2%) 23/183 (12.6%) 94/645 (14.6%) 52.9 (16.1, 75.2) 16.3 (-37.5, 50.6) 
      Influenza A 2/140 (1.4%) 6/166 (3.6%) 33/584 (5.7%) 78.4 (32.5, 95.7) 43.1 (-30.2, 78.5) 
     Influenza B 12/150 (8.0%) 17/177 (9.6%) 61/612 (9.3%) 36.9 (-18.8, 68.8) -5.2 (-86.0,  42.9) 
2016-2017      
     All Influenza 1/142 (0.7%) 3/143 (2.1%) 27/670 (4.0%) 85.1 (40.2, 98.4) 36.9 (-76.8, 83.4) 
     Influenza A 1/142 (0.7%) 3/143 (2.1%) 27/670 (4.0%) 85.1 (40.2, 98.4) 36.9 (-76.8, 83.4) 
     Influenza B - - - - - 
2017-2018      
     All Influenza 17/137 (12.4%) 25/160 (13.5%) 97/519 (18.7%) 57.2 (24.2, 76.9) 23.4 (-26.6, 54.7) 
     Influenza A 9/129 (7.0%) 11/171 (6.4%) 43/465 (9.2%) 44.0 (-16.5, 75.4) 21.6 (-56.5, 63.2) 
     Influenza B 8/128 (6.2%) 14/174 (8.0%) 54/476 (11.3%) 64.4 (24.7, 84.9) 24.9 (-40.5, 61.8) 
Models were adjusted for hospital (Hospital A vs others), log-adjusted age in months, presence of any comorbidity, prior 
year hospital admission (yes/no), distance of hospital admission from the influenza season peak (in two-week intervals), 
days from admission date to influenza PCR.  Season is included in pooled models. 
Individuals	were	considered	fully	vaccinated	if	they	received	two	current	season	vaccinations	at	least	14	days	apart	at	
least	28	days	before	their	hospital	admission	or	if	they	received	>1	vaccine	before	the	current	season	and	a	current	
season	vaccine	28	days	before	hospitalization.	Individuals	were	considered	partially	vaccinated	if	they	did	not	meet	the	
above	categories	but	did	receive	a	current	season	vaccine	28	days	before	admission.		
*Influenza	B	results	do	not	include	contribution	from	2016-17	when	influenza	B	was	not	circulating	
Abbreviations:	Vaccine	effectiveness	(VE),	confidence	interval	(CI)	
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Table 2.7 Percentage of Fully and Partially Vaccinated and Adjusted Influenza Vaccine 
Effectiveness Estimates by Season and Influenza Type Restricting to Individuals Unaffected by In 
School Influenza Vaccination Strategy 
 
No. Positive/ No. Evaluated (%) Adjusted VE (95% CI) 
 
Fully 
Vaccinated 
Partially 
Vaccinated Unvaccinated 
Fully 
Vaccinated 
Partially 
Vaccinated 
All Seasons excluding 
2016-2017 
     
     All Influenza 36/333 (10.8%) 49/406 (12.1%) 205/1303 (15.7%) 50.8 (27.7, 67.2) 22.4 (-9.5, 45.8) 
     All Influenza A 12/309 (3.9%) 17/374 (4.5%) 87 /1185(7.3%) 61.2 (29.9, 80.1) 44.4 (6.2, 68.7) 
    All Influenza B 24/321 (7.5%) 32/389 (8.2%) 118/1216 (9.7%) 42.3 (8.6, 64.9) 4.1 (-45.4, 38.1) 
2016-2017 excluding 
individuals aged 6 
years and older 
     
     All Influenza 1/138 (0.7%) 4/155 (2.5%) 27/675 (3.8%) 83.3 (32.9, 98.2) 28.2 (-86.8, 77.9) 
     Influenza A 1/138 (0.7%) 4/155 (2.5%) 27/675 (3.8%) 83.3 (32.9, 98.2) 28.2 (-86.8, 77.9) 
     Influenza B - - - - - 
Models adjusted for hospital (Hospital A vs others), log-adjusted age in months, presence of any comorbidity, prior year 
hospital admission (yes/no), distance of hospital admission from the influenza season peak (in two-week intervals), days 
from admission date to influenza PCR.  Season is included in pooled models. 
Individuals	were	considered	fully	vaccinated	if	they	received	two	current	season	vaccinations	at	least	14	days	apart	at	
least	28	days	before	their	hospital	admission	or	if	they	received	>1	vaccine	before	the	current	season	and	a	current	season	
vaccine	28	days	before	hospitalization.	Individuals	were	considered	partially	vaccinated	if	they	did	not	meet	the	above	
categories	but	did	receive	a	current	season	vaccine	28	days	before	admission.		
Abbreviations:	Vaccine	effectiveness	(VE),	confidence	interval	(CI)	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 42 
Chapter 3 Influenza Vaccine Effectiveness in the Inpatient Setting; Evaluation of 
Potential Bias in the Test Negative Design by Use of Alternate Control Groups2 
 
3.1 Author Summary 
The test negative design is commonly used to estimate influenza vaccine effectiveness. This 
study design was validated in the outpatient setting, but certain biases may persist among 
hospitalized patients. We found that VE estimates did not change consistently over two seasons 
when using alternate control groups, suggesting that the population differences in the inpatient 
setting do not lead to bias of VE estimates from the test negative design. We also found that the 
influenza vaccine did not alter the risk of non-influenza infections, an important assumption of 
the test negative design.  
3.2 Abstract 
The test negative design (TND) is used to estimate influenza vaccine effectiveness (VE) and is 
well validated in outpatient but not inpatient settings, where specific biases may differ. For 
example, the high prevalence of chronic pulmonary disease among enrollees of inpatient studies 
may lead to a non-representative control group. TND estimates are biased if influenza vaccine 
administration is associated with incidence of non-influenza viruses. We evaluated potential 
biases correlated with inpatient control group selection and effects of influenza vaccination on 
the incidence of other respiratory viruses. Patients with acute respiratory infection were enrolled 
                                                
2 Chapter 3 is in preparation for submission to the International Journal of Epidemiology. The full author list is: 
H.E. Segaloff, B. Cheng, A.V. Miller, J.G. Petrie, R.E. Malosh, C.K. Cheng, A.S. Lauring, L. Lamerato, J.M. 
Ferdinands, A.S. Monto, E.T. Martin. 
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from two hospitals during the 2014-15 and 2015-16 influenza seasons and tested for respiratory 
viruses. VE against influenza was estimated using three control groups: influenza negative, other 
respiratory virus positive, and pan-negative individuals. VE was also estimated for other 
common respiratory viruses. In 2014-15, VE was 41.1% (95% CI: 1.7%, 64.7%) using the 
influenza negative control group, 24.5% (95% CI: -42.6%, 60.1%) using the other-virus positive 
group, and 45.8% (95% CI: 5.7%, 68.9%) using the pan-negative group. In 2015-16, VE was 
68.7% (95% CI: 44.6%, 82.5%) using the influenza negative control group, 63.1% (95% CI: 
25.0%, 82.2%) using the other-virus positive group, and 71.1% (46.2%, 84.8%) using the pan-
negative group. Influenza vaccination did not alter the odds of any other respiratory virus. We 
did not find evidence of substantial bias related to control group selection or vaccine effects on 
the incidence of non-influenza viruses, supporting the use of the TND in inpatient studies. 
3.3 Introduction 
In the United States, between 140,000 and 960,000 individuals are hospitalized due to 
influenza each year, and those hospitalized are most at risk for severe influenza-related 
outcomes, including death99.  Hospitalized individuals often have chronic diseases that impact 
their ability to recover from influenza, making effective vaccines particularly important in this 
population100–102. However, the study design most commonly used to evaluate influenza vaccine 
effectiveness (VE), the test negative design (TND), has primarily been validated in outpatient 
settings. Its validity in inpatient settings is largely unknown20,26,27,43. Hospital-based studies add 
to knowledge of the full spectrum of protection afforded by the influenza vaccine. When VE 
estimates from hospital-based studies differ from estimates from ambulatory-based studies, an 
understanding of the validity of hospital-based estimates is necessary to fully interpret these 
results, and to evaluate the ability of the vaccine to prevent the most severe infections103.  
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The validity of the TND relies on various assumptions, most relevantly that influenza 
vaccination is not associated with incidence of non-influenza respiratory infections, and that the 
influenza-negative control group is drawn from the same population that gave rise to the 
cases23,24. In order to assure this comparability between cases and controls, a symptom-based 
case definition is used to restrict participants to those experiencing an acute respiratory infection 
(ARI), presumably caused by a virus or bacterium that elicits similar symptoms to influenza26,27. 
Outpatient and inpatient populations vary substantially; beyond obvious differences in illness 
severity, hospitalized patients tend to be older, frailer, and more chronically ill than patients in 
outpatient settings. There is concern that features that differentiate the inpatient population from 
the well-validated outpatient population may lead to biased VE estimates. Specifically,  the 
increased prevalence of chronic respiratory and related conditions among hospitalized adults 
may lead to biased influenza VE estimates using the TND43,19. Bias in hospital-based TND 
estimates would occur if individuals with chronic respiratory conditions such as chronic 
obstructive pulmonary disease (COPD) or congestive heart failure (CHF) have symptoms that 
mimic ARI symptoms even when they are not experiencing a true ARI. These same individuals 
may more frequently present to seek medical care. If these patients who are at an increased 
probability to test negative for influenza and are more likely to present to the hospital are also 
more likely to be vaccinated, this could bias VE estimates upwards in TND studies.  Because 
influenza vaccine may provide greater protection against severe illness compared to mild-
moderate illness, differentiating bias from a true increase in VE can be challenging. 
To understand the potential role of this selection bias in TND studies, we calculated VE 
against influenza hospitalization using three control groups that were laboratory confirmed to be 
negative for influenza infection in two influenza seasons. The 2014-15 season that was 
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dominated by a mismatched influenza A(H3N2) virus, and the 2015-16 season with a well-
matched influenza A(H1N1) virus. The control groups included the traditional "influenza-
negative" control group, an alternative “other virus positive” control group that included patients 
testing negative for influenza but positive for another respiratory virus, and a "pan-negative" 
control group including patients who were negative for all viruses. We also tested the assumption 
that influenza vaccination does not affect incidence of other respiratory viruses by calculating 
VE against pooled non-influenza respiratory viruses and specifically against respiratory syncytial 
virus (RSV) and human rhinovirus (hRV).  
3.4 Methods 
3.4.1 Participant enrollment and interview 
Participants were adults (age ≥18) hospitalized for ARI (respiratory and constitutional 
symptoms with onset in the past 10 days) at the University of Michigan Hospital (hospital A) in 
Ann Arbor, Michigan or Henry Ford Hospital (hospital B) in Detroit during the 2014-15 and 
2015-16 influenza seasons19. Enrollment occurred from November 5th 2014 to March 6th 2015 in 
2014-15 and from January 11th 2016 to April 15th 2016 in 2015-16. Eligibility criteria, 
enrollment procedures, and ARI definitions have been described previously19,104. Briefly, adults 
admitted to the hospital in the previous 72 hours with an ARI of ≤10 days duration were 
identified by daily review of electronic medical records (EMRs) by study staff. Eligible 
participants or their representatives provided written informed consent. The Institutional Review 
Boards at the University of Michigan Medical School and Henry Ford Health System approved 
all study procedures. 
 Participants were interviewed at enrollment to collect information about demographics, 
influenza vaccination, illness characteristics and subjective assessment of frailty (unexplained 
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>10 pounds weight loss [yes/no], little energy for desired activities [yes/no], difficulty walking 
100 yards [no difficulty…unable to do], difficulty carrying 10 pounds [no difficulty…unable to 
do] and frequency of low/moderate activity [more than once/week…hardly ever/never]) 103.  
 Evidence for comorbid health conditions was extracted from the EMR and used to 
calculate the Charlson Comorbidity Index (CCI) score for each patient as previously 
described103,105. Intensive care unit (ICU) admission and hospital length of stay were also 
extracted from the EMR. Influenza vaccine receipt was documented using the EMR, the state 
immunizations registry, or plausible patient self-report on the enrollment interview. Self- report 
was considered plausible if timing and location of immunization could be provided. 
3.4.2 Specimen collection and laboratory methods 
Nasal and throat specimens were acquired from enrolled patients, combined, and tested 
for influenza by reverse transcription polymerase chain reaction (RT-PCR). All primers, probes 
and protocols were developed and provided by the Influenza Division of the CDC. At a later 
date, RNA from specimens from the 2014-15 season, stored in viral transport media at -80° C, 
were re-extracted. For specimens collected during the 2015-16 season, RNA extracted for 
influenza testing during the season was stored at -80° C and thawed for additional multiplex 
testing. All extracted RNA was tested for viral pathogens using the FTD Respiratory Pathogen 
33 multiplex PCR kit (Fast Track Diagnostics). Results for hRV, coronavirus HKU1 (hCoV-
HKU1), coronavirus OC43 (hCoV-OC43), coronavirus NL63 (hCoV-NL63), coronavirus 229E 
(hCoV-229E), parainfluenza viruses 1-4, human metapneumovirus  (HMPV), human bocavirus, 
paraechovirus, enterovirus, adenovirus, and RSV were recorded. 
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3.4.3 Statistical methods 
Patients who tested positive for influenza by RT-PCR were cases. We defined three 
control groups by multiplex testing: “influenza negative”, “other virus positive”, and “pan-
negative”. Individuals with an indeterminate positive by multiplex testing (unable to determine 
presence of exponential curve) were excluded from the other virus positive and pan-negative 
control groups but were still included in the influenza positive or negative groups depending on 
their influenza status. 
Patients were considered vaccinated if they had documented or plausible self-report of 
vaccination ≥14 days before illness onset; if patients self-reported no vaccination and had no 
documentation of vaccine receipt they were considered unvaccinated. Individuals who received 
the vaccine 1 to 13 days before illness onset or who could not report either location or timing of 
vaccination and had no documentation were excluded, and individuals who received the vaccine 
after onset were considered unvaccinated. 
CCI score were categorized as 0,1,2 or ≥3. Our frailty score was defined as the sum of the 
dichotomized subjected assessments of frailty. Characteristics of cases were compared to all 
three control groups. Characteristics of vaccinated and unvaccinated enrollees were compared 
using χ2 tests or Fisher’s exact tests for categorical variables and Wilcoxon rank-sum test for 
continuous variables. 
VE was estimated separately for each influenza season and control group, and was 
calculated as 100*(1-Odds Ratio) comparing case and control patients in Firth’s corrected 
logistic regression models. Adjusted models contained sex, age group (18-49, 50-64, 65+), 
Hospital (A vs. B), frailty score, CCI, days between illness onset and specimen collection, and 
calendar time of illness onset measured in two-week windows. In addition VE using hRV 
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positive individuals and RSV positive individuals as case groups compared to hRV negative and 
RSV negative individuals, respectively, as controls was calculated. Influenza-positive individuals 
were excluded from these analyses. These models were used to test the assumption that influenza 
does not impact incidence of other viruses, any difference from the null would be evidence for 
this bias. 
3.5 Results 
3.5.1 Participant inclusion and viral testing 
In the 2014-15 season, we enrolled 756 participants; after exclusions 624 were included 
(Figure 3.1). Ninety-eight (15.7%) individuals tested positive for influenza A(H3N2) and 526 
tested negative (Figure 3.1). Of the influenza-negative individuals, 181 (34.4%) tested positive 
for a respiratory virus, and 338 (64.2%) tested negative for all viruses (Figure 3.2); 7 (1.3%) 
individuals who had indeterminate status for a non-influenza virus were excluded from analyses 
using the other virus positive or pan-negative control groups. In the 2015-2016 season, 482 
individuals were enrolled. After exclusions, 441 individuals remained in the final sample (Figure 
3.1). Eighty-seven (19.7%) individuals tested positive for influenza A(H1N1), and 354 tested 
negative . Of those 354, 107 (30.2%) tested positive for a non-influenza respiratory virus and 247 
(69.8%) tested negative for all viruses (Figure 3.2).  
3.5.2 Participant characteristics by case status and control group 
Participant demographics and clinical characteristics did not vary by control group in 
either season, with a few exceptions (Tables 3.1 and 3.2). In 2014-15, influenza positive 
individuals had significantly lower frequency of CHF and significantly lower mean frailty score 
than controls. The other virus positive group had the lowest frequency of individuals aged ≥65 
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(29.8% of the other virus group, 34.4% of the influenza negative group); opposite to the 
relationship seen in 2015-16, when participants who tested positive for a non-influenza virus 
tended to be older than influenza negative participants. In both 2014-15 and 2015-16, the other 
virus positive group had the highest frequency of individuals enrolled >4 days post illness onset. 
The other virus positive group had the lowest mean frailty compared to other control groups in 
2014-15; this trend was not seen in 2015-16 (3.1 and 3.2). In 2015-16, influenza positive 
individual had significantly less frequency of a CCI>3 and less CHF than controls. Among 
controls, a higher proportion of individuals in the other virus positive group (61.7%) had a CCI 
>3 compared to those in the influenza-negative (55.9%) control group; this was not seen in 2014-
15. 
3.5.3 Chronic Respiratory Illness by Case Status and Control Group 
Due to concerns regarding over-representation of individuals with chronic respiratory 
illness in the influenza negative control group, we examined the frequency of COPD and CHF by 
control group.  In 2014-15, prevalence of COPD was higher in the other virus positive group 
(69.1%) than in the all influenza negative group (62.4%); there was a similarly higher prevalence 
in the influenza positive group (67.3%). CHF was similarly prevalent in all control groups. In 
2015-16, COPD and CHF were distributed similarly across all control groups (Table 3.2). 
3.5.4 Participant characteristics by vaccination status 
In both seasons, roughly two-thirds of participants were vaccinated against influenza 
(Tables 3.1 and 3.2) and vaccination varied by enrollment hospital, age, race, CCI, CHF, and 
whether participants received primary care from the enrollment hospital (Tables 3.3 and 3.4). 
COPD was more prevalent among vaccinated participants in 2015-16 but not 2014-15. 
Vaccination was less frequent among cases compared to influenza-negative and pan-negative 
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controls in the 2014-15 season, but this difference was not significant between case and other 
virus positive controls (Table 3.5). In 2015-16, vaccination was significantly less frequent among 
cases compared to all control groups (Table 3.6).  
3.5.5 Influenza VE estimates using alternate control groups 
In the 2014-15 influenza season, the vaccine was 41.1% (95% CI: 1.7%, 64.7%) effective 
at preventing influenza A(H3N2)-related hospitalizations using the influenza negative control 
group, but VE was lower (24.5%, 95% CI: -42.6%, 60.1%) when other virus positive controls 
were used, though confidence intervals were wide and overlapped substantially (Figure 3.3).  VE 
was highest (45.8%, 95% CI: 5.7%, 68.9%) when using pan-negative controls. In 2015-2016, 
using the influenza negative control group, the vaccine was 68.7% (95% CI: 44.6%, 82.5%) 
effective at preventing influenza A(H1N1) associated hospitalizations. VE was consistent when 
using the other virus positive group (63.1%, 95% CI: 25.0%, 82.2%) or the pan-negative group 
(71.1%, 95% CI: 46.2%, 84.8%) as controls. 
3.5.6 VE estimates against non-influenza viruses 
In order to evaluate the assumption of the TND that the influenza vaccine is not associated with 
the incidence of non-influenza respiratory infections, we tested VE against RSV, hRV, and all 
pooled non-influenza respiratory viruses. The vaccine was not protective against any non-
influenza virus in either season. In 2014-15, VE against hRV was -34.6% (95% CI: -176.8%, 
22.8%) and VE against all non-influenza viruses was 23.3% (-18.4%, 48.1%) (Figure 3.4). In the 
2015-16 season all VE estimates against these non-influenza viruses were near 0% (Figure 3.4). 
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3.6 Discussion 
Many large network studies evaluate annual VE in various clinical settings globally30,106–
108. However, there are few direct comparisons of VE estimates generated in hospital and 
ambulatory settings from the same source population44–46,109,110  With a lack of comparative data 
from TND in outpatient and inpatient studies, differences in VE estimates from these settings are 
challenging to interpret. For example, a moderate and significant VE found in Michigan inpatient 
adults in 2014-15 was in stark contrast to VE estimated in outpatient settings that was near 0% 
both among Michigan adults and across the US58,103,111.  
In order to evaluate the hypothesis that over-inclusion of individuals with chronic 
respiratory illnesses among influenza-negative controls biases inpatient VE estimates, we 
compared influenza negative and other virus positive controls. In both seasons examined, the 
assumption that influenza-negative controls had higher frequency of chronic diseases and 
increased age was not supported. Controls did not differ consistently by age, CCI, CHF, or 
COPD.  These data suggest that the hypothesis that influenza negative control group contains an 
inappropriate frequency of patients with chronic respiratory conditions was unfounded. This is a 
particularly important conclusion for TND studies, as exacerbations of chronic respiratory 
conditions such as COPD are important complications of influenza infection and frequent causes 
of hospitalization, meaning that exclusion of these individuals to reduce bias would not be a 
viable solution.  
Our results did not indicate consistent over-estimation of VE using an influenza negative 
control group. In both 2014-15 and 2015-16, VE calculated using other virus positive controls 
had 95% CIs that overlapped those of VE calculated using influenza negative controls. In 2015-
16, VE was consistent regardless of the control group used. We did observe some variation 
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between VE estimates in the 2014-15 season, when the VE estimate using the traditional control 
group (41.1%) was higher than VE calculated using the other virus positive group (24.5%). 
However, this difference does not fully explain the discrepancy found between the outpatient and 
inpatient VE estimates that we measured in this season112. Our results suggest that while it is 
possible that selection bias accounted for a portion of the high VE in preventing hospitalization 
in 2014-15, this bias probably did not fully account for this discrepancy. It is possible that while 
a mismatched vaccine was unable to prevent mild influenza illness, it was able to prevent severe 
illness, possible supported by the lower rates of ICU admission among influenza positive 
individuals in 2014-15, a year with low VE28,113 
Other studies, mostly conducted in outpatient settings, have also shown that VE is similar 
using influenza-negative and other virus positive controls109,114,115. A recent meta-analysis 
evaluating VE using alternate control groups found no difference in VE when using influenza-
negative, other virus positive, or pan-negative control groups among 12 studies25. Similar to our 
study, more variation between estimates was observed when VE was low than when it was high. 
However, only three of the studies evaluated included inpatients, and only two included inpatient 
adults38,109,116. Both studies found no difference between VE when using alternate control groups 
109,116.Notably, like these two studies, our study used research case definitions to define 
eligibility for study enrollment. The potential for selection bias due to inclusion of patients 
without ARI is more likely when studies rely on physician directed clinical testing rather than 
rigorous case definitions as inclusion criteria. While our results are suggestive, they may not be 
generalizable to TND studies that use clinical testing or other methods to determine inclusion 
with no case definition. 
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We also tested the assumption that the influenza vaccine does not affect incidence of 
other respiratory viruses by calculating VE against these viruses. While it has been suggested 
that the influenza vaccine may increase incidence of non-influenza respiratory viruses in 
children117, most studies have found  no association between influenza vaccine receipt and 
incidence of non-influenza respiratory viruses118,119. Our results confirm these null findings in an 
inpatient setting. In the 2014-15 season there was some variation in VE estimates against non-
influenza viruses likely due to small numbers, but all point estimates were not statistically 
different than zero.  
It is possible that the true discrepancy between VE calculated using different control 
groups is larger in certain age groups, especially considering that older adults tend to be more 
frail and have more chronic illnesses than younger adults. However, our small sample size 
prevented us from stratifying by age. Another limitation to our analysis was our inability to 
differentiate between molecular detection of virus and determination of the causal agent of 
illness, a common dilemma with PCR-based testing panels. Certain respiratory viruses can be 
shed and detected via PCR for long periods of time post-infection (e.g. adenovirus) or can be 
frequently detected among asymptomatic individuals (e.g. hRV). If individuals were enrolled 
into our study with symptoms unrelated to the respiratory virus that they were shedding, we may 
have misclassified their exposure, as they would truly belong in the pan-negative control group. 
However, hRV has been shown to cause severe clinical illness in some cases, so exclusion of 
these individuals or classification of these individuals as pan-negative is also likely to cause 
bias120–122. In addition, it is possible that certain individuals with a respiratory virus were 
allocated to the pan-negative control group because they had ceased shedding their respiratory 
virus, as we enrolled individuals with onset as long as ten days before enrollment. However, time 
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from onset to enrollment was shorter in the pan-negatives compared to the other virus positive 
and influenza-positive groups. 
We did not find evidence of systematic bias due to an association between the influenza 
vaccine and the incidence of non-influenza respiratory infections, or a non-representative 
influenza-negative control group in our study. Our results indicate that non-representative 
controls and non-specific vaccine effects are not consistent sources of bias in inpatient VE 
estimates calculated in studies with a systematic case definition. These data suggest that the use 
of TNDs in VE studies enrolling influenza-infected inpatients does not introduce systematic bias.  
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Figure 3.1	Flow	Chart	of	Exclusions	for	Determination	of	the	Final	Sample	for	the	2014-15	and	2015-16	
Influenza	Seasons.	 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other	virus	positive	refers	to	participants	who	tested	negative	for	influenza	but	positive	for	a	different	
respiratory	virus.	Pan-negative	refers	to	participants	who	tested	negative	for	all	respiratory	viruses.	In	
the	2014-15	season	7	participants	who	had	an	undeterminable	PCR	result	on	one	or	more	respiratory	
virus	targets	and	did	not	test	positive	for	any	viruses	were	classified	as	influenza	negative	but	not	as	
either	other	virus	positive	or	pan-negative.	
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Figure 3.2 Respiratory Virus Counts by Two Week Period in the 2014-15 and 2015-16 Influenza 
Seasons 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
The	percent	influenza	A	positive	(H3N2	in	2014-15,	and	H1N1	in	2015-16)	is	represented	by	the	dashed	
line.	Each	color	bars	represent	counts	of	the	frequency	that	each	virus	was	detected	in	a	two-week	
period.	The	translucent	gray	bars	indicate	counts	of	individuals	who	test	negative	for	all	viruses.		
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Table 3.1 Characteristics of Influenza A(H3N2) Outcome Status Using Alternate Control 
Groups; 2014-1 
   Control Groupsa 
 Total (n=624) Influenza Positive 
(n=98) 
All Influenza 
Negative (n=526) 
Other Virus 
Positive (n=181) 
Pan-Negative 
(n=338) 
Enrolled at 
Hospital A  
341 (54.6%) 53 (54.1%) 288 (54.8%) 98 (54.1%) 186 (55.0%) 
Female Sex 337 (54.0%) 60 (61.2%) 277 (52.7%) 93 (51.4%) 181 (53.6%) 
Age Group      
     18-49 165 (26.4%) 27 (27.6%) 138 (26.2%) 48 (26.5%) 90 (26.6%) 
     50-64 239 (38.3%) 32 (32.7%) 207 (39.5%) 79 (43.6%) 126 (37.3%) 
     65+ 220 (35.3%) 39 (39.8%) 181 (34.4%) 54 (29.8%) 122 (36.1%) 
Raceb 
     
     White 329 (53.1%) 52 (53.6%) 277 (53.0%) 87 (48.1%) 185 (55.2%) 
     Black 217 (35.0%) 33 (34.0%) 184 (35.2%) 67 (37.0%) 116 (34.6%) 
     Other 74 (11.9%) 12 (12.4%) 62 (11.9%) 27 (14.9%) 34 (10.1%) 
Vaccinatedc 
421 (67.5%) 57 (58.2%) 364 (69.2%) 119 (65.7%) 240 (71.0%) 
Charlson Score      
     0 49 (7.9%) 8 (8.2%) 41 (7.8%) 15 (8.3%) 26 (7.7%) 
     1 180 (28.8%) 36 (36.7%) 144 (27.4%) 49 (27.1%) 93 (27.5%) 
     2 97 (15.5%) 12 (12.2%) 85 (16.2%) 32 (17.7%) 51 (15.1%) 
     3+ 198 (47.8%) 42 (42.9%) 256 (48.7%) 85 (47.0%) 168 (49.7%) 
Congestive Heart 
Failure 
189 (30.3%) 22 (22.4%) 167 (31.7%) 57 (31.5%) 109 (32.2%) 
Chronic 
Obstructive 
Pulmonary Disease 
394 (63.1%) 66 (67.3%) 328 (62.4%) 125 (69.1%) 200 (59.2%) 
Frailty Scored      
     Mean ± SD 1.83 ± 1.42 1.52 ± 1.33 1.88 ± 1.43 1.71 ± 1.45 1.98 ± 1.42 
Enrolled ≤4 days 
from Illness Onset 
382 (61.2%) 66 (67.3%) 316 (60.1%) 93 (51.4%) 218 (64.5%) 
Receiving Primary 
Care from 
enrollment hospital 
health systeme 
463 (74.9%) 74 (76.3%) 389 (74.7%) 134 (74.9%) 249 (74.3%) 
Length of Hospital 
Stay 
     
      Mean ± SD 4.36 ± 4.35 3.25 ± 2.28 4.56 ± 4.61 4.46 ±4.17 4.65 ± 4.86 
Intensive Care Unit 
Admission 
69 (11.1%) 6 (6.1%) 63 (12.0%) 17 (9.4%) 46 (13.6%) 
Abbreviation: SD, standard deviation 
a. Control groups used include all influenza negative enrollees and two subsets of this group. Other virus positive includes 
enrollees who tested positive for one or more respiratory viruses but negative for influenza. Pan-negative includes enrollees 
who tested negative for all viruses. Seven individuals who had unknown status for one or more viruses and did not test positive 
for any virus were excluded from the other virus positive and pan-negative groups. 
b. Four participants refused to report their racec. Participants were considered vaccinated if documented or plausible self-
reported influenza vaccine receipt was ≥14 days before illness onset; participants were considered unvaccinated if there was no 
evidence of documented vaccination and they self-reported no vaccination.d. Subjective assessments of frailty across 5 items 
were dichotomized (present/absent, difficult/not difficult, frequent/not frequent) and summed across items to create a frailty 
score (0 = not frail  …  5 = very frail). 
e. One participant had missing location of primary care physician 
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Table 3.2 Characteristics of Enrolled Patients by Influenza A(H1N1) Outcome Status Using 
Alternate Control Groups; 2015-16 
 
 
   Control Groupsa 
 Total (n=441) Influenza Positive 
(n=87) 
All Influenza 
Negative (n=354) 
Other Virus 
Positive (n=107) 
Pan-Negative 
(n=247) 
Enrolled at Hospital A 259 (58.7%) 45 (51.7%) 214 (60.5%) 67 (62.6%) 147 (59.5%) 
Female Sex 250 (56.7%) 44 (50.6%) 206 (58.2%) 69 (64.5%) 137 (55.5%) 
Age Group      
     18-49 146 (33.1%) 33 (37.9%) 113 (31.9%) 28 (26.2%) 85 (34.4%) 
     50-64 159 (36.1%) 31 (35.6%) 128 (36.2%) 42 (39.3%) 86 (34.8%) 
     65+ 136 (30.8%) 23 (26.4%) 113 (31.9%) 37 (34.6%) 76 (30.8%) 
Raceb      
     White 221 (50.8%) 43 (50.6%) 178 (50.9%) 53 (49.5%) 125 (51.4%) 
     Black 161 (37.0%) 35 (41.2%) 126 (36.0%) 35 (32.7%) 91 (37.4%) 
     Other 53 (12.2%) 7 (8.2%) 46 (13.1%) 19 (17.8%) 27 (11.1%) 
Vaccinatedc 293 (66.4%) 38 (43.7%) 255 (72.0%) 80 (75.5%) 174 (70.4%) 
Charlson Score      
     0 66 (15.0%) 21 (24.1%) 45 (12.7%) 10 (9.3%) 35 (14.2%) 
     1 91 (20.6%) 19 (21.8%) 72 (20.3%) 17 (15.9%) 55 (22.3%) 
     2 53 (12.0%) 14 (16.1%) 39 (11.0%) 14 (13.1%) 25 (10.1%) 
     3+ 231 (52.4%) 33(37.9%) 198 (55.9%) 66 (61.7%) 132 (53.4%) 
Congestive Heart 
Failure 
148 (33.6%) 19 (21.8%) 129 (36.4%) 41 (38.3%) 88 (35.6%) 
Chronic Obstructive 
Pulmonary Disease 
261 (59.2%) 38 (43.7%) 223 (63.0%) 67 (62.6%) 195 (66.6%) 
Frailty Scored      
     Mean ± SD 1.77  ± 1.43 1.62  ± 1.37 1.81  ± 1.45 1.80 ± 1.44 1.81 ±1.45 
Enrolled ≤4 days from 
Illness Onset 
280 (63.5%) 67 (77.0%) 213 (60.2%) 58 (54.2%) 155 (62.8%) 
Receiving Primary 
Care from enrollment 
hospital health systeme 
295 (66.9%) 61 (70.1%) 234 (66.1%) 81 (75.7%) 153 (61.9%) 
Length of Hospital 
Stay 
     
      Mean ± SD 4.47  ± 4.82 5.23  ± 7.50 4.28  ± 3.88 4.20 ± 3.65 4.31 ± 3.98 
Intensive Care Unit 
Admission 
50 (11.3%) 12 (13.8%) 38 (10.7%) 10 (9.3%) 28 (11.3%) 
Abbreviation: SD, standard deviation 
a. Control groups used include all influenza negative enrollees and two subsets of this group. Other virus positive includes 
enrollees who tested positive for one or more respiratory viruses but negative for influenza. Pan-negative includes enrollees who 
tested negative for all viruses. Seven individuals who had unknown status for one or more viruses and did not test positive for 
any virus were excluded from the other virus positive and pan-negative groups. 
b. Six participants refused to report their racec. Participants were considered vaccinated if documented or plausible self-reported 
influenza vaccine receipt was ≥14 days before illness onset; participants were considered unvaccinated if there was no evidence 
of documented vaccination and they self-reported no vaccination.d. Subjective assessments of frailty across 5 items were 
dichotomized (present/absent, difficult/not difficult, frequent/not frequent) and summed across items to create a frailty score (0 = 
not frail  …  5 = very frail). 
e. One participant had missing location of primary care physician 
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Table 3.3 Characteristics of Enrolled Patients by Vaccination Status; 2014-15 
 
 
 
 
 
 Total (n= 624) Vaccinated (n=421)a Unvaccinated (n=203) P-value 
Enrolled at Hospital A 341 (54.6%) 253 (60.1%) 88 (43.3%) <.0001 
Female Sex 337 (54.0%) 226 (53.7%) 111 (54.7%) 0.81 
Age Group    <.0001 
     18-49 165 (26.4%) 77 (18.3%) 88 (43.3%)  
     50-64 239 (38.3%) 169 (40.1%) 70 (34.5%)  
     60+ 220 (35.3%) 175 (41.6%) 45 (22.2%)  
Raceb    0.0001 
     White 329 (53.1%) 246 (58.7%) 83 (41.3%)  
     Black 217 (35.0%) 125 (29.8%) 92 (45.8%)  
     Other 74 (11.9%) 48 (11.5%) 26 (12.9%)  
Charlson Score    <.0001 
     0 49 (7.9%) 25 (5.9%) 24 (11.8%)  
     1 180 (28.8%) 103 (24.5%) 77 (37.9%)  
     2 97 (15.5%) 63 (15.0%) 34 (16.7%)  
     3+ 198 (47.8%) 230 (54.6%) 68 (33.5%)  
Congestive Heart Failure 189 (30.3%) 145 (34.4%) 44 (21.7%) 0.001 
Chronic Obstructive 
Pulmonary Disease 
394 (63.1%) 267 (63.4%) 127 (62.6%) 0.83 
Frailty Scorec     
     Mean ± SD 1.83 ± 1.42 1.89 ± 1.42 1.70 ± 1.42 0.10 
Enrolled ≤4 days from Illness 
Onset 
382 (61.2%) 257 (61.0%) 125 (61.6%) 0.90 
Receiving Primary Care from 
enrollment hospital health 
systemd 
463 (74.9%) 337 (80.8%) 126 (62.7%) <.0001 
Length of Hospital Stay     
      Mean ± SD 4.36 ± 4.35 4.43 ± 4.12 4.21 ± 4.80 0.03 
Intensive Care Unit 
Admission 
69 (11.1%) 44 (10.5%) 25 (12.3%) 0.49 
Abbreviation: SD, standard deviation 
a. Participants were considered vaccinated if documented or plausible self-reported influenza vaccine receipt 
was ≥14 days before illness onset; participants were considered unvaccinated if there was no evidence of 
documented vaccination and they self-reported no vaccination. 
b. Four participants refused to report their race.c.  Subjective assessments of frailty across 5 items were 
dichotomized (present/absent, difficult/not difficult,  
frequent/not frequent) and summed across items to create a frailty score (0 = not frail  …  5 = very frail). 
d. One participant had missing location of primary care physician 
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Table 3.4 Characteristics of Enrolled Patients by Vaccination Status; 2015-16 
 
 
 
 
 
 Total (n=441 ) Vaccinated 
(n=293)a 
Unvaccinated 
(n=148) 
P-value 
Enrollment at Hospital A 259 (58.7%) 201 (68.6%) 58 (39.2%) <.0001 
Female Sex 250 (56.7%) 173 (59.0%) 77 (52.0%) 0.16 
Age Group    <.0001 
     18-49 146 (33.1%) 76 (25.9%) 70 (47.3%)  
     50-64 159 (36.1%) 105 (35.8%) 54 (36.5%)  
     60+ 136 (30.8%) 112 (38.2%) 24 (16.2%)  
Raceb 
   <.0001 
     White 221 (50.8%) 173 (59.2%) 48 (33.6%)  
     Black 161 (37.0%) 87 (29.8%) 74 (51.7%)  
     Other 53 (12.2%) 32 (11.0%) 21 (14.7%)  
Charlson Score    <.0001 
     0 66 (15.0%) 20 (6.8%) 46 (31.1%)  
     1 91 (20.6%) 50 (17.1%) 41 (27.7%)  
     2 53 (12.0%) 40 (13.7%) 13 (8.8%)  
     3+ 231 (52.4%) 183 (62.5%) 48 (32.4%)  
Congestive Heart Failure 148 (33.6%) 121 (41.3%) 27 (18.2%) <.0001 
Chronic Obstructive Pulmonary 
Disease 
261 (59.2%) 195 (66.6%) 66 (44.6%) <.0001 
Frailty Scorec 
    
     Mean ± SD 1.77 ± 1.43 1.92 ± 1.45 1.47 ± 1.35 0.002 
Enrolled ≤4 days from Illness Onset 280 (63.5%) 189 (64.5%) 91 (61.5%) 0.53 
Receiving Primary Care from 
enrollment hospital health systemd 
295 (67.0%) 211 (72.0%) 84 (57.1%) 0.002 
Length of Hospital Stay     
      Mean ± SD 4.47  ± 4.82 4.20 ± 3.81 4.99 ± 6.34 0.84 
Intensive Care Unit Admission 50 (11.3%) 29 (9.9%) 21 (14.2%) 0.18 
Abbreviation: SD, standard deviation 
a. Participants were considered vaccinated if documented or plausible self-reported influenza vaccine receipt 
was ≥14 days before illness onset; participants were considered unvaccinated if there was no evidence of 
documented vaccination and they self-reported no vaccination. 
b. Seven participants refused to report their racec. Subjective assessments of frailty across 5 items were 
dichotomized (present/absent, difficult/not difficult, frequent/not frequent) and summed across items to 
create a frailty score (0 = not frail  …  5 = very frail). 
d. One participant had missing location of primary care physician 
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Table 3.5 Influenza Status by Vaccination Status, 2014-15 
 Total  Vaccinated a Unvaccinated  P Valueb 
Influenza H3N2 Positive Cases 98 57 (58.2%) 41 (41.8%)  
Control Groups     
All Influenza Negative 526 364 (69.2%) 162 (30.8%) 0.03 
Other Virus Positive 181 119 (65.7%) 62 (34.3%) 0.21 
Pan-Negative 338 240 (71.0%) 98 (29.0%) 0.02 
a	Participants	were	considered	vaccinated	if	documented	or	plausible	self-reported	influenza	vaccine	receipt	was	≥14	days	before	illness	
onset;	participants	were	considered	unvaccinated	if	there	was	no	evidence	of	documented	vaccination	and	they	self-reported	no	
vaccination.	
b.	P	values	are	comparing	the	percent	vaccinated	of	each	control	group	compared	to	the	influenza	positive	group. 
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Table 3.6 Influenza Status by Vaccination Status, 2015-16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Total  Vaccinateda Unvaccinated  P Valueb 
Influenza H1N1 
Positive Cases 
87 38 (43.7%) 49 (56.3%)  
Control Groups     
All Influenza 
Negative 
354 255 (72.0%) 99 (28.0%) <.0001 
Other Virus 
Positive 
107 81 (75.7%) 26 (24.3%) <.0001 
Pan Negative 247 174 (70.4%) 73 (29.6%) <.0001 
a	Participants	were	considered	vaccinated	if	documented	or	plausible	self-reported	influenza	vaccine	receipt	was	≥14	days	
before	illness	onset;	participants	were	considered	unvaccinated	if	there	was	no	evidence	of	documented	vaccination	and	
they	self-reported	no	vaccination.	
b.	P	values	are	comparing	the	percent	vaccinated	of	each	control	group	compared	to	the	influenza	positive	group. 
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VE	was	estimated	separately	for	each	influenza	season	using	each	control	group,	and	was	calculated	as	
100*(1-Odds	Ratio)	comparing	case	and	control	patients	in	Firth’s	corrected	logistic	regression	models.	
Adjusted	models	contained	sex,	age	group	(18-49,	50-64,	65+),	Hospital	(A	vs.	B),	frailty	score,	CCI,	days	
between	illness	onset	and	specimen	collection,	and	calendar	time	of	illness	onset	measured	in	two-week	
windows	
Other	virus	positive	refers	to	participants	who	tested	negative	for	influenza	but	positive	for	a	different	
respiratory	virus.	Pan-negative	refers	to	participants	who	tested	negative	for	all	respiratory	viruses.	In	
the	2014-15	season	7	participants	who	had	an	undeterminable	PCR	result	on	one	or	more	respiratory	
virus	targets	and	did	not	test	positive	for	any	viruses	were	classified	as	influenza	negative	but	not	as	
either	other	virus	positive	or	pan-negative.	
 
Figure 3.3 Influenza	vaccine	effectiveness	estimates	using	three	different	control	groups	in	the	
2014-15	and	2015-16	influenza	seasons.	
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Figure 3.4 Vaccine	effectiveness	against	hRV,	RSV,	and	pooled	non-influenza	viruses	in	the	2014-15	and	
2015-16	seasons. 
Abbreviations:	hRV	human	Rhinovirus,	RSV	Respiratory	Syncytial	Virus	
VE	was	estimated	separately	for	each	influenza	season	using	each	virus	separately,	and	was	calculated	
as	100*(1-Odds	Ratio)	comparing	case	and	control	patients	in	Firth’s	corrected	logistic	regression	
models.	Adjusted	models	contained	sex,	age	group	(18-49,	50-64,	65+),	Hospital	(A	vs.	B),	frailty	score,	
CCI,	days	between	illness	onset	and	specimen	collection,	and	calendar	time	of	illness	onset	measured	in	
two-week	windows	
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Chapter 4 The Impact of Obesity and Timely Antiviral Administration on Severe 
Influenza Outcomes Among Hospitalized Adults3 
 
4.1 Author Summary 
During the 2009 influenza A(H1N1)pdm09, increased influenza severity was observed among 
morbidly obese patients. Consequently, obesity was added to the list of high-risk conditions for 
severe influenza outcomes and it was recommended that obese patients be treated with 
neuraminidase inhibitors even in the outpatient setting. We found that in the hospital, where 
neuraminidase inhibitor administration is recommended for all patients upon suspicion of 
influenza infection, obese patients were treated earlier in their disease course than other patients. 
When evaluating the impact of obesity on influenza severity, it is important to take into account 
neuraminidase inhibitor treatment and treatment timing.  
4.2 Abstract 
Obesity was identified as a risk factor for severe influenza during the 2009 influenza 
A(H1N1) pandemic, but evidence of this association has been mixed since. Post-pandemic 
antiviral treatment guidelines may have increased antiviral treatment among obese individuals. 
A prospective study of adults hospitalized with laboratory-confirmed influenza in Detroit, 
Michigan in 2011-2012 and 2012-2013 was conducted.  Patient information was collected from 
interviews and medical chart abstraction. Obese (BMI≥30) and non-obese (BMI<30) participants 
                                                
3 Chapter 4 has been published as: Segaloff, H. E., Evans, R., Arshad, S., Zervos, M. J., Archer, C., Kaye, K. S., & 
Martin, E. T. (2018). The impact of obesity and timely antiviral administration on severe influenza outcomes among 
hospitalized adults. Journal of medical virology, 90(2), 212-218. 
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were compared. Late antiviral treatment (>2 days from symptom onset), obesity (30≤BMI<40), 
and morbid obesity (BMI≥40) were evaluated as predictors of lower respiratory tract disease 
(LRD), ICU admission, and length of stay (LOS) using logistic regression and inverse 
probability weighted models. 
Forty-eight participants were included in the study after exclusions and all patients 
received antiviral treatment. Participants who were obese were significantly more likely to have 
a cough and to take steroids than non-obese participants, and had a shorter time from hospital 
admission to antiviral treatment (median time from admission to treatment of 0 days for obese 
patients and 1 day for non-obese patients (p=0.001)). In all models, late antiviral treatment was 
associated with increased odds of LRD (OR: 3.9(1.1,15.9) in fully adjusted model). After 
adjustment for treatment timing, the odds of ICU admission (OR: 6.4(0.8,58.2) to 7.9( 0.9, 87.1) 
and LRD (OR: 3.3 (0.5, 23.5) to 4.0 (0.6, 35.0) associated with morbid obesity increased. 
Obese individuals were treated with antivirals earlier than others. Late antiviral treatment 
was associated with severe influenza in the hospital.  
4.3 Introduction 
Influenza virus, though usually a self-limiting infection, is associated with increased 
morbidity and mortality during annual outbreaks123. In general, older adults and individuals with 
underlying comorbid conditions are at high risk for adverse events after influenza infection124. In 
2009, the emergence of the 2009 pandemic influenza A (H1N1) virus led to an increased 
prevalence of severe outcomes among populations that had not previously been considered at 
high risk for these consequences of disease. Specifically, children and young adults were more 
likely to be hospitalized for influenza; and morbid obesity (body mass index of 40 or greater) 
was identified as a predictor of hospitalization, ICU admission and of death125,51,126. 
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Subsequent analyses using data from non-pandemic influenza seasons have left an 
unresolved picture of the relationship between obesity and influenza severity and whether this 
relationship persists beyond the influenza A (H1N1)pdm09 subtype. A study by Cocoros et al. 
regarding seasonal and pandemic influenza A(H1N1) found that obesity had a small association 
with severe influenza like illness (ILI) in seasons dominated by H1N1 before and after the 2009 
pandemic, leading to hospitalization127. However, these results were only seen in certain age 
groups in the study population and these results have not been consistently validated in other 
populations128,129.  
Differences in antiviral treatment timing add further complexity to this issue in the post-
pandemic period. A meta-analysis analyzing the relationship between obesity and influenza A 
(H1N1)pdm09 severity in 2009-2011 influenza seasons globally found that the significant 
relationship between obesity and influenza complications was attenuated and non-significant 
after adjustment for antiviral prescription timing; the authors found that obese individuals were 
less likely to receive antivirals in a timely fashion and that this treatment timing was an 
important confounder of the relationship between obesity and influenza severity130. However, in 
the United States, a recent change to antiviral treatment recommendations may have altered this 
relationship between treatment timing and weight status. After review of data from the 2009 
pandemic, the Center for Disease Control and Prevention (CDC) added morbid obesity to their 
list of indicators for high influenza severity risk and recommended that these individuals be 
prescribed antiviral treatment empirically in the outpatient setting60. These recommendations 
may lead physicians to treat hospitalized obese patients earlier than patients without a high-risk 
condition, either through empiric treatment in outpatient settings before presentation to the 
hospital, or through immediate treatment upon hospital admission. Previous studies have 
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demonstrated that treatment with oseltamivir within 48 hours of symptom onset reduces severe 
complications of influenza and that oseltamivir is most effective when given within 48 
hours131,132. However, oseltamivir is also associated with reduced duration of shedding when it is 
given within 72 hours of symptom onset, and increased survival and decreased severity for up to 
five days after illness onset133–135. If obese individuals are treated earlier than others, antiviral 
receipt timing may complicate the ability to detect an association between obesity and influenza 
severity. 
In order to evaluate the relationship between antiviral timing, obesity, and influenza 
severity, a prospective study of hospitalized influenza-positive adults in Detroit, Michigan was 
conducted. A previous study in this region found that nearly 50% of the study population had a 
body mass index (BMI) classified as obese, well over the state average of 30.7%136. The results 
of this study indicated that obese individuals were more likely than non-obese individuals to be 
admitted to inpatient care, to have hospital stays of greater than 7 days, and to have lower 
respiratory tract disease manifestations, following influenza infection, predominately with 
influenza A (H1N1)pdm09137. The aim of this current study is to use a prospective design and 
data from the 2011-2012 and 2012-13 influenza seasons to expand on the previous data linking 
obesity to influenza severity, and to evaluate the role of the timing of antiviral administration in 
this association.  
4.4 Methods 
4.4.1 Study Population 
Hospitalized adults admitted to one of five Detroit, Michigan area hospitals with 
laboratory confirmed influenza from February through April 2012 and November 2012 through 
March 2013 were prospectively identified. Participants were enrolled from Detroit Receiving 
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Hospital, Harper Hospital, Hutzel Women’s Hospital, Sinai-Grace Hospital, and Henry Ford 
Hospital. Patients were identified from a clinical microbiology laboratory results using a clinical 
alert system (Theradoc) and their eligibility status was confirmed with their treating physician. 
Patients admitted to the hospital were eligible if they were 18 years old or greater, and if they 
tested positive for influenza A (H1N1)pdm09, influenza A (H3N2), or influenza B, and if they 
had any symptom compatible with influenza like illness (ILI) including cough, chills, rhinorrhea, 
myalgia, dyspnea, diarrhea, vomiting, and/or subjective fever. Patients were excluded from the 
analysis if they had symptom duration longer than 10 days before admission and if they had a 
BMI less than 18.5. Eligible patients were approached for informed consent. 
4.4.2 Patient Survey and Data Abstraction 
After affirmative consent, patients were surveyed to determine their illness onset date, 
physical characteristics, alcohol and smoking histories, living situation, and influenza and 
pneumococcal vaccine information. There were also asked about any physical, mental, or 
emotional limitations and if they routinely used special equipment due to a health problem (i.e. 
wheelchair, cane, special bed, special telephone). All day 1 interview questions were adapted 
from the Centers for Disease Control and Prevention Behavioral Risk Factor Surveillance 
System Survey Questionnaire138. Additional information regarding demographics, insurance 
information, and medical information pertaining to symptoms, admission timing, antiviral and 
antibiotic therapy, vaccination, readmission, ICU admission, laboratory results, virus testing 
results, diagnoses and comorbidities was collected from the electronic medical record (EMR). 
Specific conditions evaluated were a history of cancer, lung disease (bronchiectasis, 
COPD/emphysema, asthma, restrictive disease, interstitial lung disease), history of heart 
conditions (myocardial infarction, coronary artery disease, coronary artery bypass grafting), 
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diabetes, renal disease, and HIV.  Steroid use, including use of glucocorticoid steroids, 
prednisone or methylprednisolone in the last month, was also abstracted from the EMR. The 
patients were interviewed again by phone 30 days after enrollment to collect information on any 
new hospital admissions and the reason for these visits as well as any visit to a doctor in a 
doctor’s office and the reason for these visits. Information on medications prescribed since 
discharge was also collected and patients were asked whether they had made diet or exercise 
changes since their discharge date. 
4.4.3 Statistical Analysis 
Severe outcomes in this study were defined as ICU admission, lower respiratory tract 
disease (intubation, hypoxia, lung infiltrates or consolidation) and increased length of stay. For 
the determination of lower respiratory tract disease, hypoxia was defined as oxygen saturation 
percentage marked as abnormal (below 94%), and lung infiltrates as well as consolidation were 
defined by a description of infiltrates or consolidation on chest x-ray impressions.  In frequency 
models, obese (BMI of 30 or greater) and non-obese (BMI less than 30) participants were 
compared; p-values were determined using Fisher’s exact tests. Differences in distributions of 
continuous variables were tested using the Wilcoxon rank-sum test. Unadjusted and adjusted 
Firth-penalized logistic models were run to predict odds of severity; unadjusted models contain 
either categorical BMI (BMI less than 30, BMI of 30 to less than 40, BMI of 40 or greater) or 
dichotomized antiviral treatment timing (late treatment defined as >2 days from symptom onset), 
adjusted models contained both variables. Inverse probability weighting (IPW) of propensity 
scores was used to efficiently adjust for age, diabetes, and poor/fair self rated health despite the 
small sample size. Diabetes was deemed the most important clinical confounder due to the 
impact of immune system disruption on influenza outcomes and to the recommendations that 
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antivirals be used promptly in these patients139,140.  Asthma was not included in the model 
because it did not improve model fit.  IPW of propensity scores was used to reduce bias in effect 
estimates by balancing the baseline characteristics between those with and without the outcome 
of interest. Due to collinearity between steroid use and other elements in the model it was not 
used as an adjustment factor. For the outcome of increased length of stay, length of stay was log-
transformed and linear regression was used to predict percentage change in length of stay. All 
statistics were run on SAS 9.4 (Statistical Analysis System). 
4.5 Results 
There were 55 individuals enrolled in this study with laboratory-confirmed influenza. 
Individuals were excluded if they had missing data on BMI, lower respiratory tract disease, or 
ICU admission. Additionally, individuals who reported symptom onset of greater than 10 days 
before admission were excluded. The final analysis was performed on the 48 individuals with 
complete data. All (N=48) participants were treated with oseltamivir, 3 of these patients were 
given oseltamivir one day before their study admission. Of these 48 participants, 34 (70.8%) 
completed the 30-day follow up survey.   
Twenty-four (50%) participants were obese and 5 (10.4%) were morbidly obese. The 
median age was 54.5 years of age in obese individuals and 60.5 years of age in non-obese 
individuals. Obese individuals had significantly shorter duration from admission to antiviral 
therapy and significantly greater frequency of steroid prescription in the prior three months 
(Table 4.1). At study enrollment, approximately 50% (n=23) of participants self-reported the 
need for special equipment due to a health problem, almost (n=28) 60% reported having 
physical, mental, or emotional limitations, over 50% (n=25) reported poor/fair health, and nearly 
80% (n=37) reported having shortness of breath that affects their quality of life. All of these self-
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reported health conditions were more common among obese patients, though these differences 
were not statistically significant (Table 4.2). Fifty percent (n=24) of participants reported 
receiving an influenza vaccine in the last year and 62.5% (n=30) reported receiving a 
pneumococcal vaccine during their lifetime (Table 4.2). 
Thirty-four individuals participated in the survey given approximately one month post-
discharge. 79.4% (n=26) of individuals reported having an appointment with their primary care 
physician, 15 (57.7%) of these appointments were follow up appointments and 20.5% (n=7) 
reported being readmitted to the hospital within 30-days of hospital discharge. Reasons for 
readmission included deep vein thrombosis, chest pain and coronary artery disease, pneumonia, 
ischemic cardiopathy, chronic obstructive pulmonary disease exacerbation, and congestive heart 
failure exacerbation.  Almost 70% (n=26) of participants reported receiving a new prescription at 
discharge and nearly 70% (n=17) of those who received a prescription completed the full dose of 
the new medication.  A variety of medications were prescribed in the 30 days post-discharge 
including antibiotics, antivirals, steroids (inhaled and ingested), blood pressure medication, pain 
medication, and blood thinners, among others. Over half (52.9%, n=18) of participants reported 
making a positive change to their diet or exercise habits 30-days after hospital discharge (Table 
4.3). There were no deaths within 30 days of discharge. 
 In univariate models, late antiviral treatment was significantly associated with increased 
odds of lower respiratory tract disease and increased length of hospitalization (OR: 3.6 (1.1, 
14.2), Percent change: 40.8 (2.6, 93.2)) (Table 4.4). After adjustment for BMI group, the odds of 
lower respiratory tract disease and ICU admission associated with late antiviral treatment 
increased in magnitude. In the IPW models the association between late antiviral treatment and 
lower respiratory tract disease remained significant (OR: 3.9 (1.1, 15.9)).  
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In the univariate model, obese individuals (BMI from 30 to less than 40) had significantly 
shorter length of hospitalization than non-obese individuals (Percent change: -29.2 (-49.6, -
0.6))(Table 4.4). Obesity and morbid obesity were also associated with increased odds of ICU 
admission and lower respiratory tract disease, and these relationships were monotonic, though 
not significant (Table 4.4). After adjustment for late-antiviral treatment the odds of lower 
respiratory tract disease and ICU admission increased in the obese group, though they did not 
reach statistical significance.  
4.6 Discussion 
This study demonstrated that antiviral treatment within two days of symptom onset was 
associated with reduced odds of lower respiratory tract disease among adults hospitalized with 
laboratory-confirmed influenza. In 2011, the Advisory Committee on Immunization Practices 
(ACIP) released their updated recommendations for antiviral treatment. They recommended that 
all hospitalized patients with suspected influenza be treated empirically, even before 
confirmation of influenza status60.The results of this study add to the existing literature that 
support this treatment recommendation change by emphasizing the importance of early antiviral 
treatment on improving patient outcomes141,142. Late antiviral treatment also appears to be an 
important confounder between obesity and influenza severity, as the likelihood of severe disease 
increased among obese individuals after adjustment for treatment in all models. These findings 
add to previous observations of the connection between antiviral treatment and obesity; a 2016 
paper examined antiviral treatment among hospitalized patients from 2010-2015 and found that 
individuals with high risk conditions, including morbid obesity, were significantly more likely 
than non-obese individuals to receive antivirals; however the 2016 study did not evaluate timing 
of therapy61.  
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This study took place at hospitals in Detroit, Michigan, a city with high levels of obesity 
and poverty143. As expected in hospitals in an underserved area, many participants had self-
reported poor health in addition to the need for special medical equipment and physical, mental, 
or emotional limitations. Forty six percent of patients received health insurance from Medicaid 
or a Medicare/Medicaid combination and an additional 4% had no insurance. Individuals with 
public insurance are more likely to visit the emergency department over their primary care 
physician. It is unclear whether or not this is due to decreased access to their primary care 
physician, more complex conditions that require emergency facilities, or a preference for the 
hospital over outpatient clinics144,145. In the current study, the increased use of the emergency 
room among those with public insurance is reflected in the high readmission rate (20.6%) 
reported from respondents to the 30-day survey. Encouragingly, 52.9% of participants who 
completed the 30-day survey reported efforts to improve their diet or exercise routine post-
hospitalization, indicating that the hospital discharge may have the potential to be an effective 
time to counsel the patient on modifiable health behaviors.  
There are limitations to this analysis. The in-hospital observational nature of the study 
complicated our ability to study some commonly used severity endpoints. Reverse causation 
could have masked associations between timely antiviral treatment and severe outcomes if 
individuals were treated when admitted to the ICU or if lower respiratory tract disease was 
already present at the time of treatment.  Lower than expected enrollment, particularly during the 
mild 2011-12 season, presented numerous difficulties. Though steroid use was likely an 
important confounder of obesity and severe influenza, steroid use could not be adjusted for due 
to collinearity between steroids and other adjustment factors. A variety of other confounders 
were able to be adjusted for using inverse-probability weighting despite the small sample size; 
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however, it is possible that residual confounding remains. Future studies should be conducted to 
re-evaluate the associations studied in this analysis, as the small sample size led to a reduction in 
statistical power.  
The findings of this prospective study highlight the need to evaluate confounding from 
antiviral treatment timing when studying the relationship between obesity and influenza severity. 
Additionally, the association between late antiviral treatment and increased likelihood of serious 
disease highlights the importance of timely antiviral treatment. This reinforces the treatment 
recommendations from the ACIP and emphasizes the need for continued evaluation of antiviral 
prescription rates among hospitalized adults. 
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Table 4.1 Patient Characteristics by Obesity Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristics Total 
(N=48) 
BMI≥30 
(N=24) 
BMI<30  
(N=24) 
P Value1 
Age (median, range) 59.0 (21-91) 54.5 (21-83) 60.5 (21-91) 0.30 
BMI (mean, 95% CI) 30.3 (27.6, 33.0) - - - 
Days from Admission 
to Antiviral Treatment 
(median, range) 
0.0 (0.0-6.0) 0.0 (0.0-4.0) 1.0 (0.0-6.0) 0.001 
 N (% of Total) N (% of Obese) N (% of Not Obese) P Value3 
Female Sex 23 (47.9%) 11 (45.8%) 12 (50.0%) 0.77 
Race4    0.45 
     White 5 (10.6%) 2 (8.7%) 3 (12.5%)  
     Black 39 (83.0%) 21 (91.3%) 18 (75.0%)  
    Other 3 (6.4%) 0 (0.0%) 2 (8.3%)  
Symptoms     
     GI Symptoms 20 (41.7%) 7 (29.2%) 13 (54.2%) 0.08 
     Cough 37 (77.1%) 22 (92.1%) 15 (62.5%) 0.02 
     Fever 26 (54.2%) 15 (62.5%) 11 (45.8%) 0.25 
     Chills 22 (45.8%) 13 (54.2%) 9 (37.5%) 0.25 
     Shortness of Breath 29 (60.4%) 17 (70.8%) 12 (50.0%) 0.14 
     Fatigue 12 (25.0%) 4 (16.7%) 8 (33.3%) 0.18 
Clinical Factors     
     Diabetes 16 (31.2%) 8 (33.3%) 7 (29.2%) 0.76 
     Chronic Obstructive         
P  Pulmonary Disease  
11 (22.9%) 7 (29.2%) 4 (16.7%) 0.30 
     Asthma 8 (16.7%) 5 (20.8%) 3 (12.5%) 0.44 
     Congestive Heart   
F   Failure 
11 (22.9%) 5 (20.8%) 6 (25.0%) 0.73 
     Sepsis 20 (41.7%) 11 (45.8%) 9 (37.5%) 0.56 
     Steroid Use5 13  (27.7%) 10 (43.5%) 3 (12.5%) 0.02 
1P values are the result of Wilcoxon tests 
23 obese patients were given oseltamivir one day before admission, these individuals were classified as treated 0 days 
from hospital admission 
3P values are the result of Fisher’s exact tests.  
4One individual with obesity is missing race status 
5One individual with obesity is missing information on steroid medication 
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Table 4.2 Survey Results by Obesity Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristics Total  
(N=48) 
BMI≥30 
(N=24) 
BMI<30  
(N=24) 
P Value1 
 N (Column %) N (Column %) N (Column %)  
Self-Reported Limitations 28 (58.3%) 16 (66.7%) 12 (50.0%) 0.24 
Self-Reported Poor/Fair 
Health 
25 (52.1%) 15 (62.5%) 10 (41.7%) 0.24 
Self-Reported Need for 
Equipment Due to Medical 
Condition  
23 (47.9%) 13 (54.2%) 10 (41.7%) 0.39 
Report that Shortness of 
Breath Affects Quality of 
Life 
37 (77.0%) 20 (83.3%) 17 (70.8%) 0.30 
100 Cigarette Smoking 
History 
24 (50.0%) 12 (50.0%) 12 (50.0%) 1.0 
Influenza Vaccine Receipt 24 (50.0%) 13 (54.2%) 11 (45.8%) 0.56 
Pneumonia Vaccine 
Receipt 
30 (62.5%) 14 (58.3%) 16 (66.7%) 0.55 
 Median 
(Range) 
Median 
(Range) 
Median (Range) P Value2 
Alcoholic Drinks per Day 
in Past Month 
0 (0-5) 0 (0-4) 0 (0-5) 0.22 
Number of Children in the 
Household 
0 (0-5) 0 (0-2) 0 (0-5) 0.30 
1P values are the result of Fisher’s exact tests 
2P values are the result of Wilcoxon tests 
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Table 4.3 Day 30 Survey Results by Obesity Status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristics  Total 
(N=34) 
BMI≥30 
(N=20) 
BMI<30 
(N=14) 
P Value1 
Hospital 
Readmission 
7 (20.6%) 3 (15.0%) 4 (28.6%) 0.41 
Visit to PCP 26 (79.4%) 16 (80.0%) 10 (71.4%) 0.69 
Positive Diet 
Change  
18 (52.9%) 11 (55.0%) 7 (50.0%) 0.77 
New Medication 
Prescribed2 
26 (67.6%) 14 (73.7%) 12 (85.7%) 0.67 
Completed Dose of 
New Medication3 
17 (68.0%) 11 (84.6%) 6 (50.0%) 0.10 
1.P Values are calculated from Fisher’s exact tests 
 2. One individual with obesity is missing information on new medication prescription 
3. Percentages are calculated out of the number of individuals who reported having a new medication prescribed. One 
obese individual who reported receiving a new prescription had missing information on dose, so this percentage was 
calculated out of 13.  
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Table 4.4 Predictive Models of Influenza Severity among Hospitalized Adults Treated with 
Antivirals 
  Univariate Associations  Multivariable Model IPW Model 
ICU Admission (OR, 
95% CI) 
 
 Admitted to ICU  
(N, %)(N=7) 
   
BMI<30 (N=24) 2 (8.3%) 1.0 1.0 1.0 
30≤BMI<40 (N=19) 3 (13.8%) 1.9 (0.3, 12.6) 2.9 (0.5, 20.9) 2.5 (0.4, 17.0) 
BMI≥40 (N=5) 2 (11.6%) 6.4 (0.8, 58.2) 7.9 (0.9, 87.1) 7.8 (0.8, 88.9) 
Late Antiviral Treatment 
(N=27) 
6 (22.2%) 4.13 (0.8, 42.2) 5.1 (0.9, 53.4) 5.2 (0.95, 54.3) 
Lower Respiratory 
Tract Disease (OR, 95% 
CI) 
 
 Lower 
Respiratory Tract 
Disease (N, %) 
(N=17) 
   
BMI<30 (N=24) 7 (41.7%) 1.0 1.0 1.0 
30≤BMI<40 (N=19) 7 (36.8%) 1.4 (0.4, 5.0) 2.1 (0.5, 8.6) 3.0 (0.8, 12.3) 
BMI≥40 (N=5) 3 (60.0%) 3.3 (0.5, 23.5) 4.0 (0.6, 35.0) 4.0 (0.5, 37.5) 
Late Antiviral Treatment 
(N=27) 
13 (48.1%) 3.6 (1.1, 14.2) 4.2 (1.2, 17.7) 3.9 (1.1, 15.9) 
Length of Stay (Percent 
Change, 95% CI) 
Length of Stay  
(Median, Range) 
(5, 1-17) 
   
BMI<30 (N=24) 5 (1-17) 0.0 0.0 0.0 
30≤BMI<40 (N=19) 4 (1-8) -29.2 (-49.6, -0.6) -24.1 (-46.0, 6.7) -26.8 (-47.5, 2.1) 
BMI≥40 (N=5) 5 (2-8) -13.6(-49.8, 48.7) -12.0 (-48.3, 49.3) -11.3 (-49.3, 
55.3) 
Late Antiviral Treatment 
(N=27) 
5 (1-17) 40.8 (2.6, 93.2) 32.5 (-4.1, 83.2) 37.2 (-.3, 88.9) 
Univariate associations model displays Firth corrected univariate associations 
Multivariable model displays Firth corrected associations adjusted for BMI and late antiviral treatment (treatment >2 days 
from symptom onset compared to treatment ≤2 days from onset)  
IPW model displays inverse probability weighted models adjusted for age, diabetes and poor/fair self-rated health 
Length of stay models were modeled as log(length of stay); results were transformed to display percent changes. 
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Chapter 5 Severe Morbidity Among Hospitalized Adults with Acute Influenza and 
Other Respiratory Infections; 2014-15 and 2015-164 
 
5.1 Author Summary 
During the 2009 influenza A(H1N1)pdm09, young adults and morbidly obese patients were at 
increased risk for severe influenza. During the post-pandemic period, it is important to 
understand whether these risk factors persist, and whether they are only associated with influenza 
A(H1N1)pdm09 infection, or also influenza A(H3N2) infection. Furthermore, in order to support 
recommendation for universal vaccination as well as neuraminidase inhibitor administration for 
hospitalized patients with suspected influenza, it is important to establish the effectiveness of 
these interventions at prevention of influenza severity. We found that frail patients and patients 
who did not visit the doctor in the past year were most at risk for severe influenza outcomes. We 
also found that neuraminidase inhibitor administration reduced hospital length of stay only 
among vaccinated patients, suggesting either that vaccination and antiviral treatment interact in 
their reduction of influenza severity, or that there are unexplained differences in vaccinated and 
unvaccinated patients in our study. 
5.2 Abstract 
Our objective was to identify predictors of severe acute respiratory infection in 
hospitalized patients and understand the impact of vaccination and neuraminidase inhibitor 
                                                
4 Chapter 5 has been published as: Segaloff, H. E., Petrie, J. G., Malosh, R. E., Cheng, C. K., Ferdinands, J. M., 
Lamerato, L., Lauring A.S., Monto A.S. & Martin, E. T. (2017). Influenza Vaccination and Treatment with Antiviral 
Agents Among Hospitalized Adults in the 2014–2015 and 2015–2016 Influenza Seasons. 
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administration on severe influenza. We analyzed data from a study evaluating influenza vaccine 
effectiveness in two Michigan hospitals during the 2014-2015 and 2015-2016 influenza seasons. 
Adults admitted to the hospital with an acute respiratory infection were eligible. Through patient 
interview and medical record review, we evaluated potential risk factors for severe disease, 
defined as ICU admission, 30-day readmission, and hospital length of stay. Two hundred sixteen 
of 1119 participants had PCR-confirmed influenza. Frailty score, Charlson score, and tertile of 
prior-year health care visits were associated with length of stay. Charlson score >2  (OR:1.5[1.0, 
2.3]) was associated with ICU admission. Highest tertile of prior-year visits (OR:0.3[0.2, 0.7]) 
was associated with decreased ICU admission. Increasing tertile of visits (OR: 1.5[1.2, 1.8]) was 
associated with 30-day readmission. Frailty and prior-year health care visits were associated with 
30-day readmission among influenza-positive participants. Neuraminidase inhibitors were 
associated with decreased length of stay among vaccinated participants with influenzaA (HR:1.6 
[1.0, 2.4] ).  Overall, frailty and lack of prior-year health care visits were predictors of disease 
severity. Neuraminidase inhibitors were associated with reduced severity among vaccine 
recipients. 
5.3 Introduction 
It is widely recognized that seasonal respiratory illness, which peaks in fall and winter in 
temperate regions, is associated with corresponding peaks in doctor’s office visits and hospital 
admissions [146,147]. Numerous respiratory pathogens are associated with hospitalization; notably, 
influenza, human metapneumovirus, respiratory syncytial virus, rhinovirus, and parainfluenza 
virus; all of which cause similar symptoms [6].    However, influenza-associated illness accounts 
for a substantial proportion of these medical events [147,148].  Influenza is a viral pathogen that 
causes an estimated 12,000 to 56,000 deaths in the United States annually [149].  Influenza-
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related severe outcomes, such as death, ICU admission, or the need for invasive mechanical 
ventilation, generally occur in elderly individuals or individuals with numerous comorbidities; 
however, previously healthy adults are also at risk for serious illness [150,151].  
During the 2009 influenza A(H1N1) pandemic, individuals thought to be at low risk for 
severe influenza, such as those under the age of 65 and without recognized underlying 
conditions, were hospitalized at a higher than expected rate [49]. During the pandemic, previously 
unknown risk factors for influenza severity were identified with morbid obesity being one of the 
most consistently identified factors [50,51].  In post-pandemic seasons the age of those 
hospitalized for influenza A(H1N1)pdm09 infection increased along with an increase in the 
severity of influenza-related pneumonia [53–55]. There was, paradoxically, a corresponding 
decrease in the use of antiviral treatment initially, though rates of treatment have since risen 
[55,61].  With the continued circulation of the A(H1N1) pandemic strain along with A(H3N2) and 
B viruses it is critical to identify and monitor groups at risk for severe disease in order to 
optimize strategies, including use of neuraminidase inhibitors and vaccine prioritization when the 
vaccine supply is limited, to prevent adverse outcomes. 
In order to identify predictors of influenza and acute respiratory illness (ARI) severity 
and, specifically, to understand the impact of vaccination and neuraminidase inhibitor 
administration on illness severity, we present data from adults hospitalized with ARI from two 
hospitals in Southeast Michigan over the 2014-2015 and 2015-2016 influenza seasons. Severe 
outcomes evaluated include ICU admission, length of stay (LOS), and 30-day readmission.  
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5.4 Methods 
5.4.1 Participant Enrollment, Interview and Specimen Collection 
Participants were adults hospitalized for ARI at University of Michigan Hospital (UMH, 
Hospital A) in Ann Arbor, Michigan and Henry Ford Hospital (HFH, Hospital B) in Detroit. 
Enrollment occurred from November 5th 2014 to March 6th 2015, and from January 11th 2016 to 
April 15th 2016. Staff reviewed electronic medical records (EMRs) daily to identify newly 
admitted patients (≤72 hours) with ARI as previously described [152]. Eligible participants were 
approached, and they or their proxy provided written consent for participation in the study. All 
study procedures were approved by the Institutional Review Boards of the University of 
Michigan Medical School and the Henry Ford Health System. 
Patients were interviewed at enrollment to collect information about demographics, 
influenza vaccination status, general health status, illness characteristics, and subjective 
assessment of frailty (unexplained >10 pounds weight loss [yes/no], little energy for desired 
activities [yes/no], difficulty walking 100 yards [no difficulty…unable to do], difficulty carrying 
10 pounds [no difficulty…unable to do] and frequency of low/moderate activity [more than 
once/week…hardly ever/never]).  Number of health care encounters in the past year and 
evidence of neuraminidase inhibitor prescription from the study hospital admission were 
extracted from EMRs. Information about comorbid health conditions were also extracted to 
calculate the Charlson Comorbidity Index (CCI) for each patient. The following outcome 
variables were collected from the EMR: death, ICU admission, ventilator use, length of stay, and 
30-day readmission. Outcomes that were experienced by more than 10 influenza-positive 
participants, including ICU admission, length of stay, and 30-day readmission, were used in 
models. 
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5.4.2 Laboratory Methods 
Nasal and throat swabs collected at enrollment were combined and tested for influenza 
viruses using reverse transcriptase polymerase chain reaction (RT-PCR). All primers, probes and 
protocols were developed and provided by the Influenza Division of the CDC. They were 
designed for detection of universal influenza A and B, and for subtype and lineage identification. 
All tests were performed in the investigators’ laboratory at the University of Michigan School of 
Public Health.  
5.4.3 Influenza Vaccination Status 
Individuals were considered vaccinated if they had documentation or plausible self-report 
of influenza vaccine receipt ≥14 days before illness onset. Documented vaccination status was 
determined based on documentation from the EMR or state immunization registry. Plausible 
self-report was defined as reporting both the approximate date and location of vaccination. 
Individuals were considered unvaccinated if they had no evidence of documentation of 
vaccination and self-reported no vaccination. Participants were excluded if they had an 
incomplete self-report of vaccination (e.g. missing date or location) and no additional 
documentation or if they were vaccinated <14 days before illness onset.  
5.4.4 Statistical Methods 
CCI scores were categorized as 0, 1, 2, or 3 or greater; high CCI was defined as greater 
than 2. Frailty was defined as the presence of up to 5 dichotomized variables taken from the 
enrollment interview that were summed and weighted by the number of questions answered, as a 
few participants either refused to answer or answered “don’t know” to either one or two of the 
frailty questions [152,153].  Total prior-year health care visits were defined as all inpatient and 
outpatient visits for any reason to a UM or HF Health System affiliated clinic in the previous 
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year. Tertiles of prior year health care visits among all participants were calculated, and the 
variable was expressed as either 0 visits, or visits falling into the first (1-8 visits), second (9-21 
visits), or third (≥22 visits) tertile. Long length of stay was defined as length of stay of >8 days. 
When used as a continuous outcome, LOS was log-transformed and beta coefficients were 
analyzed as percent change of LOS. 
Participants were compared in frequency models using Pearson χ2 test or Fisher’s exact 
test. Firth’s penalized logistic regression models were used to predict the odds of severe illness 
by various risk factors. Firth’s method was used to reduce small-sample bias and improve model 
fit in the context of quasi-separation. Hospital site (UMH or HFH), sex, age (18-49, 50-64, 65+), 
frailty score, and CCI>2 were included in adjusted models a priori. Tertile of prior-year health 
care visits was included based on their significance in univariate models; this variable was 
modeled categorically for the outcomes of ICU admission and hospital length of stay and 
ordinally for 30-day readmission due to the monotonic relationship between these variables.  For 
analyses restricted to influenza A positive individuals, influenza A subtype, influenza 
vaccination were included as adjustment factors. Cox proportional hazard models, censoring on 
death, were used to estimate the impact of antiviral treatment on hospital length of stay. 
Neuraminidase inhibitor administration was modeled as a time varying covariate indicating the 
day in the hospital admission when participants were treated. The models were adjusted for 
covariates associated with increased hospital length of stay in the risk factor analysis, weighted 
frailty score and tertile of prior-year health care visits. All statistics were completed using SAS 
(release 9.4, SAS Institute). Statistical significance was defined as a 95% confidence interval that 
did not include the null value.  
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5.5 Results 
5.5.1 Demographics and Outcomes by Influenza Status 
We enrolled 1199 adults with ARI; 727 from the 2014-2015 season and 472 from the 
2015-2016 season. Eighty (7%) hospitalizations were excluded due to missing or incomplete 
information on vaccination status, influenza status, or Charlson score, leaving 1119 participants 
in the analysis. 
Two-hundred sixteen (19%) participants had PCR-confirmed influenza virus infection. 
Influenza-positive participants were significantly less likely to have received influenza vaccines 
(Table 5.1). Half of participants had a CCI >2 but this percentage was significantly lower in 
individuals with influenza (41.2%) compared to those testing negative (52.2%). Among 
influenza positive participants there were 2 deaths, 22 ICU admissions, 10 invasive ventilations 
and 19 instances of long LOS (>8 days); these outcomes were observed in similar frequencies 
between the influenza positive and negative populations.  Thirty-day readmission was 
significantly less frequent among influenza-positive participants compared to those testing 
negative (Table 5.1).  
One-hundred and eleven participants were infected with influenza A(H3N2) viruses, 90 
with influenza A(H1N1)pdm2009 and 15 with influenza B viruses; models restricted to 
influenza-positive individuals excluded individuals with influenza B virus infection. There was a 
higher frequency of influenza A(H1N1)pdm09 infection among participants who were 18-49 
years old (37% with H1N1 vs. 26% with H3N2, p=0.10), though this difference was not 
statistically significant (Table 5.2). CCI (p=0.02), tertile of prior year health care visits (p=0.05) 
and vaccination status (p=0.02) were associated with influenza A subtype; individuals with a 
CCI of 0, no health care visits in the prior year and who were unvaccinated were more frequently 
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infected with influenza A(H1N1)pdm09 (Table 5.2). A higher percentage of participants infected 
with H1N1 were admitted to the ICU, put on an invasive ventilator, and had LOS >8 days 
compared to those infected with H3N2 (Table 5.2). 
5.5.2 Models Prediction Severe ARI and Influenza-associated ARI 
Higher frailty and increased tertile of prior-year health care visits were associated with 
increased 30-day readmission among influenza-positive participants (Table 5.3). Individuals with 
the highest tertile of prior-year health care visits had decreased odds of ICU admission compared 
to those with no prior-year visits regardless of influenza status (Table 5.3). Frailty score was 
associated with longer LOS among all participants but not among participants with influenza-
associated ARI (Table 5.3).  
5.5.3 Neuraminidase Inhibitor Prescription 
One hundred fourty-seven (68%) influenza-positive participants were treated with neuraminidase 
inhibitors. Treatment varied by enrollment hospital; over 75% of influenza-positive patients from 
Hospital A were treated compared to only 57% from Hospital B (p=0.01) (Table 5.4). 
Neuraminidase inhibitor administration also varied by time from illness onset to admission; 73% 
of participants admitted within two days were treated compared to 59% of those admitted later 
(p=0.02) (Data not shown). Median length of stay was lower among those with timely antiviral 
treatment (2.0 days) compared to those with late antiviral treatment (3.0 days) or no treatment 
(3.0), however the median length of stay did not vary significantly. 
Clinical testing for influenza varied significantly by enrollment hospital, 74% of 
influenza-positive participants from Hospital B by research testing received a clinical influenza 
test compared to 90% from Hospital A. Only 10% of participants from either hospital without a 
clinically positive influenza test were treated with neuraminidase inhibitors (Data not shown). 
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The influenza-positive population was further stratified by vaccination status. Vaccinated 
individuals who were treated with neuraminidase inhibitors had a significantly reduced LOS 
(HRdischarge:1.6, 95% CI: 1.0, 2.4], p=0.04) compared to those who were untreated (Table 5.5). 
Other severe outcomes were not evaluated in this analysis due to insufficient sample size. 
5.6 Discussion 
Our study identified risk factors for severe influenza-associated ARI and all-cause ARI 
among hospitalized patients over two influenza seasons. Given that viral etiology is often 
unknown at admission when many treatment decisions are made, it is important to understand 
severity of ARI of all causes in the hospital. Of note, 65% of participants were tested clinically 
for influenza and the majority of these tests were initiated the day of or the day after hospital 
admission. Despite the timely testing, it may take many hours for PCR results to be available to 
the clinician and rapid influenza tests are known for their low specificity. For these reasons, 
treatment decisions should be made before viral etiology is known in most cases. Higher frailty 
score was associated with longer LOS, and having 0 prior-year health care visits was associated 
with higher odds of ICU admission. Frailty is a well-known predictor of severity and death, 
especially among the elderly, though many studies do not consider frailty when studying 
influenza severity [154–156].  The increased severity among those without prior-year health care 
visits may indicate that individuals who are unlikely to seek care present to the hospital with the 
most severe illnesses. Increased health care visits over the prior year were also associated with 
increased, rather than reduced, 30-day readmission indicating that 30-day readmission may be, in 
part, a measure of underlying chronic conditions [157].  
We evaluated the impact of vaccination and neuraminidase inhibitor administration on 
influenza severity. Neuraminidase inhibitors were significantly associated with decreased LOS 
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among vaccinated individuals only after stratification by vaccination status. While the 
association between neuraminidase inhibitor administration and reduced influenza severity has 
been emphasized, the interaction between vaccination and neuraminidase inhibitors is not well 
documented or understood [134,158]. Though this result offers an interesting potential relationship 
between antiviral treatment, vaccination, and influenza severity, the extremely small sample size 
in this stratified population necessitates repeated demonstration of this association in larger, 
future studies. 
In light of this result and other evidence in the literature, it is critical that hospitalized 
influenza-positive patients are treated with neuraminidase inhibitors [68,134].  We found that just 
67% of participants with PCR-confirmed influenza were prescribed neuraminidase inhibitors 
though treatment is recommended for all hospitalized patients with suspected or confirmed 
influenza. Treatment varied significantly by enrollment hospital; over 40% of influenza-positive 
participants at Hospital B did not receive neuraminidase inhibitors, compared to 23% at Hospital 
A. While all participants are tested for influenza by our research team, not every patient receives 
a clinical influenza test during their hospital stay. This appeared to impact treatment decisions, as 
very few individuals without a clinically positive influenza test were treated despite the 
recommendation that hospitalized individuals with suspected influenza be treated empirically. 
These numbers indicate a need to continue public health messaging directed at nurses and 
physicians to encourage empiric treatment and to keep influenza on the list of possible diagnoses 
during influenza season. Additionally, participants were less likely to be treated if they were 
admitted to the hospital >2 days after symptom onset. This reflects the widely held opinion that 
antiviral drugs are only effective within 2 days of symptom onset. While studies have shown that 
effectiveness is higher when neuraminidase inhibitors are given promptly, there is evidence 
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among hospitalized patients with influenza that treatment within 5 days of symptom onset 
improves survival [65,134,158]. 
Continued interest in the potential for vaccination to reduce influenza severity stems from 
the vaccine effectiveness (VE) estimates from the 2014-15 influenza season, which primarily 
consisted of influenza A viruses that were antigenically drifted from the Northern Hemisphere 
vaccine strains [152,159].  VE estimates from the 2014-15 season were higher in hospital studies 
than in ambulatory care studies, where they were not significantly different from zero [111,152,160].  
This could indicate that influenza vaccination reduces severity as well as incidence; this 
hypothesis has been previously evaluated but results are mixed [28,29,56,57]. We did not find an 
association between severity and vaccination. Observational studies of severity, such as ours, as 
well as evaluations of interventions such as vaccination are often impacted by confounding by 
indication and other challenges.  
 Overall, the small number of influenza-positive participants in this study led to reduced 
power, which may explain the few significant predictors of influenza severity. The in-hospital 
observational nature of the study complicated our ability to study some commonly used severity 
endpoints such as mechanical ventilation and death. Additionally, selection into this study 
depended on hospital admission prior to enrollment, potentially increasing the number of older 
individuals with comorbidities who are more likely to be admitted to the hospital with a less 
severe disease. We accounted for this in our analysis by adjusting for age, CCI, and prior-year 
health care visits, but residual confounding is always a concern. In addition, when calculating the 
tertile of prior-year health care visits, we could only access visits within the hospital study sites 
or their associated outpatient clinics, and the majority of individuals who had no visits did not 
get their regular care within these two systems. However, when the population was restricted to 
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those who did get regular care at our study sites in a sensitivity analysis, the trends of increased 
severity among those with no prior-year visits remained. 
 In conclusion, we identified frailty and number of prior-year health care visits as 
predictors of all-cause and influenza-associated ARI severity. Our finding that vaccinated 
patients who received neuraminidase inhibitors had decreased LOS needs confirmation from 
future studies, but also adds to the evidence that administration of neuraminidase inhibitors to 
hospitalized patients reduces influenza severity and reinforces current treatment 
recommendations in the hospital [12,68,135,161].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 92 
Table 5.1 Demographics and Outcomes of Hospitalized Adults with ARI by Influenza Status 
 Total  N=1119 Influenza Positive  N=216 Influenza Negative  N=903 P Value3 
Characteristics N (Column %) N (Column %) N (Column %)  
Sex    0.68 
     Male 501 (44.7%) 94 (43.5%) 407 (45.1%)  
     Female 618(54.8%) 122 (56.5%) 496 (54.9%)  
Age    0.44 
     18-49 323 (28.9%) 67 (31.0%) 256 (28.3%)  
     50-64 415 (37.1%) 72 (33.3%) 343 (38.0%)  
     ≥65 381 (34.0%) 77 (35.7%) 304 (33.7%)  
Race1    0.62 
     White (Non-Hispanic) 583 (52.7%) 114 (54.0%) 469 (52.3%)  
     Black (Non-Hispanic) 392 (35.4%) 76 (36.0%) 316 (35.3%)  
     Other 132 (11.9%) 21 (10.0%) 111 (12.4%)  
Site of Enrollment    0.47 
     Hospital A 636 (56.8%) 118 (54.6%) 518 (57.4%)  
     Hospital B 483 (43.2%) 98 (45.4%) 385 (42.6%)  
Year    0.12 
     2014-2015 664 (59.3%) 118 (54.6%) 546 (60.5%)  
     2015-2016 455 (40.7%) 98 (45.4%) 357 (39.5%)  
Charlson Score    0.01 
     0 119 (10.6%) 33 (15.3%) 86 (9.5%)  
     1 283 (25.3%) 62 (28.7%) 221 (24.5%)  
     2 157 (14.0%) 32 (14.8%) 125 (13.8%)  
     ≥3 560 (50.0%) 89 (41.2%) 471 (52.2%)  
Frailty Score (median(IQR)) 0.25 (0.0,0.40) 0.25 (0.0-0.50) 0.40 (0.20-0.60) 0.04 
BMI Category2    0.51 
     <18.5 42 (3.9%) 4 (1.9%) 38 (4.3%)  
     18.5-24.9 267 (24.7%) 53 (25.7%) 214 (24.5%)  
     25-29.9 284 (26.3%) 53 (25.7%) 231 (26.4%)  
     30-39.9 315 (29.1%) 65 (31.6%) 250 (28.6%)  
     ≥40 173 (16.0%) 31 (15.1%) 142 (16.2%)  
Number of Healthcare Visits 
(Tertiles) 
   0.61 
     0 128 (11.4%) 28 (13.0%) 100 (11.1%)  
     1 349 (31.2%) 72 (33.3%) 277 (30.7%)  
     2 318 (28.4%) 60 (27.8%) 258 (28.6%)  
     3 324 (29.0%) 56 (25.9%) 268 (29.7%)  
Vaccination Status    <0.01 
     Vaccinated 750 (67.0%) 113 (52.3%) 637 (70.5%)  
     Unvaccinated 369 (33.0%) 103 (47.7%) 266 (29.5%)  
Death 15 (1.3%) 2 (1.0%) 13 (1.4%) 0.56 
ICU 126 (11.3%) 22 (10.2%) 104 (11.5%) 0.58 
Invasive Ventilator 48 (4.3%) 10 (4.6%) 38 (4.2%) 0.78 
LOS >8 Days 108 (9.7%) 19 (8.8%) 89 (9.9%) 0.63 
30 day Readmission 167 (14.9%) 16 (7.4%) 151 (16.7%) <0.01 
112 individuals have missing Race information 
238 individuals have missing BMI information 
3P values are from chi square tests or Fisher’s exact tests when appropriate 
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Table 5.2 Demographics and Outcomes of Enrolled Patients Hospitalized with Influenza A 
Associated ARI by Subtype 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Total N=201 H3N2 N=111 H1N1 N=90  
Characteristics N (Column %) N (Column %) N (Column %) P Value3 
Sex    0.20 
     Male 90 (44.8%) 43 (48.7%) 43 (47.8%)  
     Female 111 (55.2%) 68 (61.3%) 47 (52.2%)  
Age      0.10 
     18-49 y 62 (30.8%) 29 (26.1%) 33 (36.7%)  
     50-64 y 68 (33.8%) 36 (32.4%) 32 (35.6%)  
     ≥65 y 71 (35.3%) 46 (41.4%) 25 (35.2%)  
Race1      0.22 
     White (Not Hispanic) 106 (53.8%) 63 (57.3%) 43 (49.4%)  
     Black  71 (36.0%) 34 (30.9%) 37 (42.5%)  
     Other 20 (10.1%) 13 (11.8%) 7 (8.0%)  
Site of Enrollment      0.29 
     Hospital A 111 (55.2%) 65 (58.6%) 46 (51.1%)  
     Hospital B 90 (44.8%) 46 (41.4%) 44 (48.9%)  
Charlson Score      0.02 
     0 31 (15.4%) 10 (9.0%) 21 (23.3%)  
     1 59 (29.3%) 39 (35.1%) 20 (22.2%)  
     2 27 (13.4%) 13 (11.7%) 14 (15.6%)  
     ≥3 84 (41.8%) 49 (44.1%) 35 (38.9%)  
Frailty Score 
(median(IQR)) 
0.25 (0.0,0.40)  0.20 (0.0-0.5) 0.40 (0.0-0.40) 0.89 
BMI Category2      0.11 
     <18.5 4 (1.7%) 4 (3.6%) 0 (0.0%)  
     18.5-24.9 47 (24.0%) 24 (21.8%) 23 (28.4%)  
     25-29.9 49 (25.1%) 33 (30.0%) 16 (19.7%)  
     ≥30 91 (49.2%) 49 (44.6%) 42 (51.9%)  
Year      <0.01 
     2014-15 107 (53.2%) 107 (96.4%) 0 (0.0%)  
     2015-16 94 (46.8%) 4 (3.6%) 90 (100.0%)  
Total Number of 
Healthcare Visits In the 
Last Year (Tertiles) 
     0.05 
     0 25 (12.4%) 8 (7.2%) 17 (18.9%)  
     1 64 (31.8%) 34 (30.6%) 30 (33.3%)  
     2 58 (28.9%) 34 (30.6%) 24 (26.7%)  
     3 54 (26.9%) 35 (31.5%) 19 (21.1%)  
Vaccination Status      0.02 
     Vaccinated 106 (52.7%) 67 (60.4%) 39 (43.3%)  
     Unvaccinated 95 (46.1%) 44(39.6%) 51 (56.7%)  
Death 2 (1.0%) 1 (0.9%) 1 (1.1%) 1.00 
ICU 20 (10.0%) 7 (6.3%) 13 (14.4%) 0.06 
Invasive Ventilator 9 (4.5%) 1 (0.9%) 8 (8.9%) 0.01 
LOS >8 Days 18 (9.0%) 5 (4.5%) 13 (14.4%) 0.02 
30 day Readmission 16 (8.0%) 10 (9.0%) 6 (6.7%) 0.61 
14 individuals are missing race information 
210 individuals are missing BMI information 
3P values reflect results of Pearson Chi-square tests or Fisher’s exact test when appropriate. P values for continuous 
variables represent results of Wilcoxon tests 
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Table 5.3 Predictors of Severe Disease in Participants with All-Cause ARI and Influenza A 
Associated ARI 
 
 
 
 
 
 
 
 
  
 ARI1 (N=1072) Influenza A Positive (N=188) 
 ICU  
(OR, 95% CI) 
LOS 
 (Percent Change, 
95% CI) 
30 Day 
Readmission 
(OR, 95% CI) 
ICU  
(OR, 95% CI) 
LOS 
 (Percent Change, 
95% CI) 
30 Day 
Readmission 
(OR, 95% CI) 
Predictors       
Male Sex 1.5 (1.0, 2.2) 6.1 (-0.5, 13.1) 1.1 (0.8, 1.6) 0.7 (0.3, 1.8) -5.0(-19.2, 11.7) 0.4 (0.1, 1.4) 
Age       
     18-49 1.0 0.0 1.0 1.0 0.0 1.0 
     50-64 1.0 (0.6, 1.6) 3.6 (-4.4, 12.3) 0.9 (0.6, 1.3) 1.1 (0.3, 3.6) 3.2 (-16.1, 26.9) 1.5 (0.3, 7.7) 
      ≥65 1.0 (0.6, 1.6) 0.4 (-7.7, 9.1) 0.6 (0.4, 1.0) 1.0 (0.3, 3.4) 6.6 (-13.8, 31.9) 1.2 (0.3, 6.2) 
Site of Enrollment       
     Hospital A 1.0 0.0 1.0 1.0 0.0 1.0 
     Hospital B 0.8 (0.5, 1.2) -0.7 (-7.3, 6.2) 1.4 (1.0, 2.1) 0.7 (0.2, 2.0) -8.1 (-23.2, 9.9) 2.7  (0.9, 9.0) 
Charlson Score >2 1.5 (1.0, 2.3) 21.7 (13.3, 30.7) 1.8 (1.2, 2.7)* 1.6 (0.5, 5.7) 8.5 (-11.0, 32.2) 1.1 (0.3, 4.2) 
Vaccination - - - 1.0  (0.3, 3.1) -6.1 (-22.4, 13.6) 0.9 (0.3, 3.5) 
Frailty Score2 1.5 (0.8, 3.0) 22.7 (9.3, 37.5)* 1.4 (0.8, 2.5) 1.0 (0.1, 6.1) 31.4 (-4.5, 80.9) 8.9 (1.2, 78.0)* 
Total Visits3 
(Tertiles) 
  1.5 (1.2, 1.8)*   2.5 (1.2, 5.8)* 
     0 1.0 0.0  1.0 0.0  
     1 0.6 (0.4, 1.1) -18.8 (-21.1, -
1.7)* 
 0.3 (0.1, 1.0)* -11.7 (-33.1, 16.6)  
     2 0.6 (0.3, 1.0) -9.3 (-18.9, 1.6)  0.2 (0.0, 0.8)* -4.2 (-28.3, 28.0)  
     3 0.3 (0.2, 0.7)* -11.2 (-21.3, 0.2)  0.1 (0.0, 0.8)* -10.0 (-35.1, 24.9)  
Influenza A 
Subtype 
      
     H3N2 - - - 1.0 0.0 1.0 
     H1N1 - - - 1.9 (0.7, 5.2) 11.1 (-5.7, 30.9) 0.8 (0.3, 2.4) 
1Adjusted models contain male sex, age group, enrollment site, Charlson score, weighted frailty score, total annual healthcare visits, 
and influenza status.  Influenza A subtype and vaccination were also included in models restricted to influenza A positive adults. 
2OR and percent changes reflect the impact of a one-unit increase in weighted frailty score. 
3Total number of annual healthcare visits is modeled categorically except in models predicting 30-day readmission where it is modeled 
ordinally and OR represent change in odds for a one tertile increase  
*indicates significance at the 5% confidence level 
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Table 5.4 Demographics by Antiviral Prescription Timing Among Participants with Laboratory 
Confirmed Influenza 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Timely Antivirals1 
N=86 
Late Antivirals N=61 No Antivirals N=69 P Value4 
Characteristics N (Row %) N (Row %) N (Row %)  
Sex      0.75 
     Male 40 (42.6%) 26 (27.7%) 28 (29.8%)  
     Female 46 (37.7%) 35 (28.7%) 41 (33.6%)  
Age      0.31 
     18-49 31 (46.3%) 21 (31.3%) 15 (22.4%)  
     50-64 27 (37.5%) 21 (29.2%) 24 (33.3%)  
      ≥65 28 (36.4%) 19 (24.7%) 30 (39.0%)  
Race2      0.21 
     White 51 (44.7%) 32 (28.1%) 31 (27.2%)  
     Black 30 (39.5%) 19 (25.0%) 27 (35.5%)  
     Other 4 (19.0%) 8 (38.1%) 9 (42.9%)  
Site of Enrollment      0.01 
     Hospital A 54 (45.8%) 37 (31.4%) 27 (22.9%)  
     Hospital B 32 (32.6%) 24 (24.5%) 42 (42.9%)  
Year      0.24 
     2014-2015 42 (35.6%) 33 (28.0%) 43 (36.4%)  
     2015-2016 44 (44.9%) 28 (28.6%) 26 (26.5%)  
Influenza 
Type/Subtype 
   0.23 
     A/H3N2 37 (33.3%) 35 (31.5%) 39 (35.1%)  
     A/H1N1 42 (46.7%) 24 (26.7%) 24 (26.7%)  
     B 7 (46.7%) 2 (13.3%) 6 (40.0%)  
Charlson Score      0.36 
     0 17 (51.5%) 8 (24.2%) 8 (24.2%)  
     1 17 (27.4%) 21 (33.9%) 24 (38.7%)  
     2 14 (43.7%) 9 (28.1%) 9 (28.1%)  
     ≥3 38 (42.7%) 23 (25.8%) 28 (31.5%)  
Frailty Score 0.20 (0.0-0.40) 0.40 (0.20-0.60) 0.40 (0.20-0.60) 0.20 
Obese3      0.22 
     Yes 39 (40.6%) 31 (32.3%) 26 (27.1%)  
     No 43 (39.1%) 26 (23.6%) 41 (37.3%)  
Number of Health 
Care Visits 
(Tertiles) 
     0.52 
     0 11 (39.3%) 8 (28.6%) 9 (32.1%)  
     1 28 (38.9%) 15 (20.8%) 29 (40.3%)  
     2 23 (38.3%) 21 (35.0%) 16 (26.7%)  
     3 24 (42.9%) 17 (30.4%) 15 (26.8%)  
Vaccination Status    0.85 
     Yes 46 (40.7%) 30 (26.6%) 37 (32.7%)  
     No 40 (38.8%) 31 (30.1%) 32 (31.1%)  
Length of Stay 
(median, IQR) 
2.0 (2.0-4.0) 3.0 (2.0-5.0) 3.0 (2.0-5.0) 0.17 
1Timely antivirals refers to antivirals within 2 days of symptom onset 
25 individuals are missing race information 
310 individuals are missing BMI information 
4P values are from chi square tests or Fisher’s exact tests when appropriate 
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Table 5.5 Hazards of Discharge Related to Antiviral Treatment Timing 
 Overall  (N=201) Vaccinated (N=106) Unvaccinated (N=95) 
Predictors  Hazard Ratio 
(95% CI) 
P Value Hazard Ratio (95% 
CI) 
P Value Hazard Ratio (95% 
CI) 
P Value 
Antiviral Treatment  1.1 (0.8, 1.5) 0.44 1.6 (1.0, 2.4) 0.04 0.9 (0.5, 1.4) 0.52 
Frailty Score 0.5 (0.3, 1.0) 0.04 0.6 (0.3, 1.3) 0.17 0.5 (0.2, 1.2) 0.11 
Total Visits (Tertiles)       
Tertile 0 ref  Ref  ref  
Tertile 1 1.6 (1.0, 2.7) 0.05 0.5 (0.1, 1.6) 0.23 1.6 (0.9, 2.9) 0.09 
Tertile 2 1.3 (0.8, 2.1) 0.32 0.3 (0.1, 1.0) 0.05 1.3 (0.7, 2.4) 0.40 
Tertile 3 1.5 (0.9, 2.4) 0.13 0.4 (0.2, 1.2) 0.09 1.6 (0.8, 3.5) 0.21 
1Models contain all predictors in the table 
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Chapter 6 Summary and Conclusions 
 
6.1 Summary of Findings 
Overall, this dissertation examined two topics, the effectiveness of the influenza vaccine 
against hospitalization and the impact of influenza vaccination and neuraminidase inhibition on 
severe influenza outcomes. VE against hospitalization was explored in two ways, first influenza 
VE against hospitalization was studied in an understudied group, hospitalized children in Israel 
in chapter 2. Secondly, in chapter three, we examined a potential bias of VE studies in the 
hospital setting. We used alternate control groups to determine whether inclusion of individuals 
without a true ARI caused bias in VE estimates against hospitalization. In chapters 4 and 5 we 
examined predictors and prevention of influenza severity. In chapter 4 we evaluated whether 
obesity was a predictor of severe influenza among hospitalized adults in Detroit, and determined 
whether antiviral treatment practices differed for obese versus non-obese patients. Finally, in 
chapter 5, we examined predictors of influenza severity among hospitalized adults in one 
A(H1N1)pdm09 dominated season and one A(H3N2) dominated season and evaluated the ability 
of influenza vaccination and treatment with neuraminidase inhibitors to reduce severe ARI and 
influenza. The results of these studies are described below, with emphasis on their implications, 
strengths and limitations. 
6.1.1 Aim 1 
Influenza VE is frequently estimated against medically attended illness in ambulatory 
care centers and hospitals in many countries across the world30,107,108,162. In the Middle East there 
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are very few estimations of VE published, and VE against hospitalization has not previously 
been calculated. In addition, it is recommended that children under the age of 9 receive two 
influenza vaccines in the first season that they are vaccinated, however few studies have 
evaluated the impact of full vs. partial vaccination in the hospital13,14,37. Understanding the 
effectiveness of the vaccine in a setting where vaccination rates are relatively low but the vaccine 
is universally recommended is important for public health messaging to reinforce guidelines. 
 In the first analysis presented in this dissertation, we demonstrated that the influenza 
vaccine was effective against hospitalization in Israeli children over three influenza seasons. 
Consistently, influenza VE was much higher in children who were fully vaccinated, and VE was 
generally not significantly effective in partially vaccinated children. This result reinforces 
guidelines that recommend two influenza vaccines in the first season of vaccination. Despite the 
recommendation by the Israeli Ministry of Health that all individuals over 6 months of age be 
vaccine annually, only 34% of children in our analysis received a current season influenza 
vaccine. Special attention is frequently paid to children with comorbid conditions, as they are 
often at high risk for severe influenza-related outcomes. However, in our study, children with 
comorbidities had similarly low rates of vaccination. Our results, which demonstrate the 
effectiveness of influenza vaccines against severe influenza in healthy children and children with 
comorbidities, reinforce guidelines from the Ministry of Health and could be used to demonstrate 
the importance of annual vaccination. 
  We used retrospective medical data from hospital records through Clalit Health Services, 
an Israeli provider and insurer, to calculate influenza VE. Influenza vaccines in Israel are only 
available at scheduled primary care visits and occasional government-sponsored school 
vaccination events in particular age groups. In addition, very few Israelis switch health care 
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insurers throughout their lifetime. For these reasons, the medical records used facilitated very 
detailed measurement of lifetime influenza vaccination. We were able to take advantage of this 
very accurate exposure information to not only have an systematic measure of current season 
vaccination, but also vaccination since birth, which allowed us to determine full versus partial 
vaccination status in a more accurate manner than previous analyses42.  
 Overall, we showed high VE for both influenza A and B. VE for influenza A in particular 
was striking; VE was 81% in 2015-16, 71% in 2016-17, and 46% in 2017-18. These estimates 
were higher than the estimates produced for young children in Israeli outpatient studies in this 
season, perhaps suggesting the superiority of the vaccine at preventing severe disease47,48.  Our 
population was very young, 61% of the children in our study and 45% of the influenza positive 
population were under 2 years of age. Pooled VE across the three seasons was nearly identical 
when the population was stratified by age (<2 and ≥2 years of age). However, it appeared that 
children under 2 had lower vaccine effectiveness against influenza B compared to children over 
the age of 2. Unfortunately the sample size did not allow for further investigation of this 
potential difference by age. In any case, the widely significant VE among children aged 6 
months through 8 years, including children with comorbidities, provides strong reinforcement for 
influenza vaccination in Israeli children. These data can be used for public health messaging to 
improve vaccination rates across Israel. 
6.1.2 Aim 2 
The test negative design has been used to study influenza VE for many years, and this 
study design has been well-validated in the outpatient setting20,26,27. However, there have been 
few evaluations of the validity of this design among inpatients43. In particular, the high 
prevalence of comorbidities among inpatient adults with symptoms that mimic ARI symptoms is 
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of concern. If patients with these comorbidities are likely to be enrolled in a TND study without 
a true ARI, it could cause significant bias in the study, particularly because these patients with 
numerous comorbidities may be more likely to seek care for an illness and may be more likely to 
be vaccinated. 
In Aim 2, we evaluated whether inclusion of patients without a respiratory virus was 
biasing VE estimates. Specifically, we tested all samples for the 2014-15 and 2015-16 seasons of 
our hospital based TND study, and used three control groups when calculating VE: all influenza 
negative (traditional control group), non-influenza other virus positive, and pan-negative. Our 
results did not show a consistent difference between influenza VE by control group, indicating 
that the inclusion of individuals without an ARI did not bias the VE estimates. However, we did 
see some differences, though confidence intervals were wide, between the other virus positive 
and influenza negative VE estimates in the 2014-15 season.  
Numerous other studies have used other virus positive and pan-negative control groups to 
determine the validity of VE estimates109,114,115. However, very few of these studies have taken 
place in inpatient settings, where this type of bias is more likely to occur. A recent meta-analysis 
by Feng et al. on this topic indicated that the past literature, consisting primarily of studies from 
outpatient settings, had results consistent with those reported here, providing evidence that this 
bias is not occurring in TND studies25. Interestingly, the studies with the lowest VE had the most 
variation in VE estimates between control groups, similar to what we observed in the 2014-15 
season.  
The results of this analysis point to the strengths of the HAIVEN study. In this study, 
patients are enrolled according to a strict case definition based on patient symptoms recorded 
during a review of the admission note. The results of our analysis indicate that this strategy 
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allows us to correctly identify patients with an ARI without biasing our results. As many studies 
around the world use similar methods to identify potentially eligible patients, this result is 
encouraging as it indicates that the TND is a valid study design for use in the inpatient setting in 
addition to the outpatient setting. However, this validity is not ensured in studies that do not use 
a strict case definition to enroll patients. 
6.1.3 Aim 3 
During the 2009 influenza A(H1N1) pandemic, morbidly obese individuals were at high 
risk for severe influenza outcomes such as ICU admission, mechanical ventilation, and 
death51,125,126. As a result of this increased severity, obesity was added to the list of high risk 
conditions for influenza, indicating that obese patients should be treated with neuraminidase 
inhibitors for any suspected medically attended influenza illness60.  In the post-pandemic period, 
it has been a priority to understand whether this risk factor for severe influenza is still relevant 
and whether it applies to both circulating influenza A strains, or only influenza A(H1N1)pdm09.  
In Aim 3, we examined whether obesity was a risk factor for influenza severity in a 
prospective study of influenza-positive adults hospitalized in Detroit. Participants were 
interviewed in the hospital and then again 30 days after discharge to get details on their disease 
course as well as any positive health changes that they made post-hospitalization. This study 
took place during the 2011-12 influenza season, which was a very mild season. Due to the low 
number of influenza-positive patients identified, enrollment was extended into the 2012-13 
season, though only 55 individuals were enrolled. This small sample was a challenge, but we 
used inverse probability weighted models to adjust for confounding without compromising 
power.  
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We did not find a significant association between obesity or morbid obesity and any of 
the tested metrics of influenza severity, though the extremely small sample size was likely a 
factor. All individuals enrolled in the study were treated with neuraminidase inhibitors, but obese 
patients were treated significantly sooner after hospital admission. While all individuals who are 
hospitalized with influenza are recommended to be treated with neuraminidase inhibitors 
empirically, it is possible that physicians were influenced by the inclusion of morbid obesity on 
the ACIP list of high risk conditions for influenza and treated these patients empirically while 
waiting for confirmation of illness for the other patients.  
Late antiviral treatment (treatment >2 days post illness onset) was significantly associated 
with increased odds of lower pulmonary disease. This result, despite the small size, reinforce 
guidelines for empiric treatment at hospital admission and mirror results from numerous studies 
indicating that rapid treatment with neuraminidase inhibitors is more effective than late 
treatment141,142.  
Antiviral treatment timing was related to both obesity status and severe influenza 
outcomes, and is therefore a possible confounder between obesity and severe influenza. If obese 
patients are routinely treated with neuraminidase inhibitors more rapidly than other patients, the 
relationship between obesity and severe influenza could be masked by different treatment 
practices. In our study, the likelihood of severe disease associated with obesity increased after 
adjustment with antiviral treatment, though the sample size was not sufficient to evaluate this 
relationship further. Future studies examining the relationship between obesity and severe 
influenza should take antiviral treatment practices into account. 
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6.1.4 Aim 4 
Individuals who are hospitalized for influenza are at risk for severe outcomes beyond 
hospitalization, such as mechanical ventilation, ICU admission and death. Understanding risk 
factors for severe influenza outcomes would allow us to identify individuals for rapid 
administrations of antivirals and prioritization of vaccination in the case of a pandemic. In 
seasons when the influenza vaccine is not effective, understanding the full protection that 
vaccination affords beyond prevention of illness is important to effectively prevent severe 
disease.   
In Aim 4, we used the data from the Michigan site of the HAIVEN study from the 2014-15 
and 2015-16 seasons to identify predictors of severe influenza and estimate the impact of 
vaccination and neuraminidase inhibition on severe outcomes. As the 2014-15 influenza season 
was dominated by influenza A(H3N2) circulation and the 2015-16 season was dominated by 
influenza A(H1N1)pdm09, we were able to compare differences between hospitalized patients 
with each type of influenza. As previously reported, individuals hospitalized with influenza 
A(H1N1)pdm09 were younger and were previously “healthier” (had lower Charlson score and 
less past year healthcare visits)49. A higher percentage of individuals with influenza 
A(H1N1)pdm09 were also admitted to the ICU, put on a mechanical ventilator, and had a long 
(>8 days) hospital length of stay. This could indicate that influenza A(H1N1)pdm09 led to more 
severe outcomes than influenza A(H3N2), or it could indicate that the patient infected with 
A(H1N1)pdm09, the “healthier” younger adults, do not  present to the hospital unless they have 
a very severe illness. 
In adjusted models, higher frailty score was associated with longer LOS, and having zero 
prior-year health care visits was associated with higher odds of ICU admission. Frailty is a well-
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established predictor of influenza severity. The association between less prior-year healthcare 
visits and severity may support the A(H1N1)pdm09 results, that individuals who do not 
frequently seek care present to the hospital with a more severe disease.   
We used Cox proportional hazard models to evaluate whether neuraminidase inhibitor 
administration is associated with increased hospital length of stay. We found that neuraminidase 
inhibitor administration significantly reduced hospital length of stay among influenza –positive 
patients who were vaccinated, but it did not impact length of stay among unvaccinated patients. 
This result could indicate synergy between the impact of vaccination and antiviral treatment on 
influenza severity. However, it is also possible that this result is related to difference in severity 
at hospital admission between vaccinated and unvaccinated individuals.  If vaccinated 
individuals also happen to be individuals who frequently seek care and present to the hospital 
with less severe illness it may be easier to see the impact of antivirals in this group.  
6.2 Strength and Limitations 
The data used for the chapter 2 came from medical records from Clalit Health Services, the 
largest medical insurer and provider in Israel. These data contain very complete vaccination 
information. All Israelis are entitled to medical care, and very few Israelis change insurers 
throughout their lifetime, as all insurers are geographically dispersed across the country. For this 
reason, we had access to incredibly complete vaccination information from birth. As 
confirmation of vaccination is generally a very difficult task in VE studies in countries where 
there is not universal medical care, having such a detailed registry of vaccination history among 
hospitalized patients was very valuable. In addition, we are confident that exposure 
misclassification was a minimal problem in this analysis. 
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The data source for this study, however, is also a limitation. Currently, there is not a VE 
network in Israel enrolling hospitalized patients. Consequently, to complete this analysis, we 
used a retrospective review of hospital records. For this reason we were unable to employ a case 
definition and relied on physician driven testing to identify our study sample. It is possible that 
individuals who did not have an ARI were included in our sample. If more severely ill children 
with more comorbid conditions were more likely to be tested for influenza without ARI 
symptoms and also more likely to be vaccinated, this could have biased our study and inflated 
our VE results. However, our results were in line with those from other studies. In addition, 
while influenza positivity was low in our study, it was within rates that had been previously 
reported.  
Our use of a retrospective medical record review was appropriate for generation of the first 
VE estimates against hospitalization from Israel. Our encouraging results, showing significant 
VE for fully vaccinated children over three seasons, may encourage others to invest in a hospital 
network study. While our methods were appropriate for an initial assessment of VE in the region, 
it would beneficial to have a prospectively enrolling TND study to confirm our results. 
In chapter 3, our ability to test our specimens for a variety of pathogens from the same 
extracted material using a multiple PCR kit allowed us to ensure that our results were 
comparable throughout the entire study. With the multiplex kit, we were able to test for over 20 
viral pathogens using the same extraction on the same PCR plate. This was an advantage, as it 
ensured that different run times or freeze thaw cycles did not make identification of certain 
specimens more likely within a sample.  
On the other hand, the study design in which these specimens were collected was designed 
specifically for identification of influenza. Individuals were enrolled in the study up to ten days 
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post illness onset and nares swabs were used to collect the specimens. While this method is 
appropriate for identification of influenza, some other viral pathogens do not shed as long as 
influenza. In addition, viral material may be difficult to isolate in sufficient titers for 
identification without using a nasopharyngeal swab. If this is the case than there may have been 
participants who had a false negative swab for respiratory viruses and were included in the pan-
negative group rather than the other virus positive group erroneously. Individuals could have also 
been “false positives”. Some viruses are shed for a long period of time even without active 
illness. If a participant was admitted to the hospital with respiratory symptoms that were 
unrelated to the virus that they tested positive for, they could have been erroneously included in 
the other virus positive group when they should have been in the pan-negative group. As we 
showed, influenza vaccination was not related to the incidence of a non-influenza virus. This 
potential outcome misclassification is not likely to be differential to the exposure, however it still 
could impact our VE results. 
The other major limitation of this analysis was the inability to definitively show lack of 
bias through the estimates produced. Having VE estimates from different control groups that are 
similar to one another is good evidence that control group selection is not biasing our study, 
however, because our study was not powered to detect these differences, simply not having 
statistically significantly different VE estimates does not ensure that there is no bias. However, if 
this bias were consistently impacting inpatient TND design studies, we would expect consistent 
differences between the other virus positive and influenza negative control groups. The VE 
estimates from the different control groups in 2015-16 were nearly identical, indicating that this 
bias was not a factor in this season. The differences in VE seen in the 2014-15 season are likely 
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due to random variation, but a more thorough statistical test in a larger population would be 
necessary to provide more thorough evidence. 
The study design and modeling strategy used in chapter 4 allowed for some useful 
conclusions to be drawn despite a very small sample size. The prospective nature of this study 
was a major strength; influenza positive patients were enrolled in the study and given a day 1 
survey and 71% of patients who gave a day 1 survey responded to a day 30 survey as well. This 
design allowed for the collection of high quality data, which is important with such few 
participants, as even a small amount of misclassification could have large impacts on the effect 
estimates.  
Using inverse probability weighting of propensity scores to remove confounding allowed 
us to reduce bias in our estimates without overfitting our models. This strategy allowed us to 
remove some confounding, which would not have been possible using standard statistical 
methods due to the extremely small sample size. Despite our efforts, confounders were not 
perfectly balanced between our exposed and unexposed populations. We were unable to include 
steroid use in our weighted model, which was a potentially important confounder. Unfortunately, 
in the propensity score model predicting late antiviral treatment, steroid use was collinear with 
other confounders and its inclusion in the model negatively impacted model fit.  
Due to the in-hospital nature of the study, we are unable to confirm that our outcomes, 
such as ICU admission and lower pulmonary disease, occurred before antiviral treatment. In 
particular, it is possible that participants who came to the hospital looking more ill with lung 
infiltrates or hypoxia could have been given antivirals soon after admission. In addition, patients 
admitted straight into the ICU may have been given antivirals upon arrival. This would bias our 
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associations to the null, making it less likely for us to see an effect of early antiviral treatment on 
severity. 
In chapter 5, we used data from the HAIVEN study to understand predictors and 
prevention of influenza severity. Using data collected from a test-negative design study had 
benefits. These studies are routinely collected in many settings, so if this type of analysis can be 
successfully conducted using these data, it could allow for rapid understanding of the 
effectiveness of neuraminidase inhibitors or vaccination on preventing severe influenza 
outcomes in the case of a pandemic. In addition, nesting this study in a test negative design study 
means that we had access to very detailed information about hospital course and patient 
characteristics. In addition to gaining access to each patient’s medical record to collect 
information about comorbidities and disease course in the hospital, we also interviewed each 
patient upon enrollment. Detailed information on vaccination was collected, as this the main 
exposure in influenza VE studies. Having this high quality information on each patient allowed 
us to evaluate a variety of potential predictors for influenza severity as well as multiple outcomes 
including ICU admission, 30-day readmission, and hospital length of stay. 
Our relatively small number of influenza positive participants limited our ability to 
evaluate all outcomes when stratifying by vaccination status. Consequently, we were only able to 
use our continuous outcomes, length of hospital stay. If individuals with serious comorbidities 
have extended hospitalizations due to management of their comorbidity only, then this outcome 
would not reflect influenza severity. Similar issues are present with other outcomes used in 
chapter 5 and throughout the dissertation. Thirty-day readmission was associated with comorbid 
conditions and correlated best with increased number of past-year health care visits while other 
severe outcomes were related to less past-year health care visits. It is possible that 30-day 
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readmission is more of a measure of health care seeking behavior then influenza severity. The 
advantage of 30-day readmission over other outcome measures is that it occurs well after 
hospital admission and well after administration of neuraminidase inhibitors. The limitation with  
the other in-hospital outcomes is that they take place so close to the exposure that there may not 
be enough time to see the impact of treatment. New outcomes that are both good measures of 
influenza severity and that take place well after neuraminidase inhibitor administration may be 
necessary to fully understand the impact of neuraminidase inhibitor administration on severe 
influenza. 
Another challenge with this study was interpreting the result that neuraminidase inhibitor 
administration was only effective when stratifying by vaccination, even though vaccination was 
not significantly effective at reducing hospital length of stay. As mentioned, the two ways to 
interpret this result are that influenza vaccination and antiviral treatment act synergistically at 
reducing severe influenza, or that there is some sort of selection bias of confounding masking the 
association that is removed when stratifying by vaccination status. More work is needed to 
determine the cause of this observation. 
6.3 Future Work 
Two limitations that continued to present themselves throughout the chapters of this 
dissertation were the difficulty classifying participants in a hospital-based study; particularly, 
how do we determine the severity of their illness upon hospital admission and how can we use 
this information to improve our research; and how to find severe outcomes that both occur after 
the exposures of interest and are true measures of severity. 
Both of these problems are challenging to solve, and are difficulties of hospital-based 
studies that have been expressed in other contexts. While every study in this dissertation has 
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encountered at least one of these difficulties, sometimes both, no study was designed specifically 
to solve these problems. Even though comorbid conditions, frailty, and older age are consistently 
identified as predictors of influenza hospitalization and overall likelihood of death from 
influenza in the literature, these same factors were not identified as consistent predictors of 
influenza severity in our hospital-based studies. In fact, in multiple chapters, the positive 
relationship between previously healthy individuals and individuals who do not frequently seek 
medical care and influenza severity has been highlighted. We have hypothesized that individuals 
who frequently seek care, and possibly have serious comorbid conditions may present and be 
admitted to the hospital with a less severe illness.  
The same factors that are related to care seeking with a less severe illness may also be 
related to vaccination and antiviral treatment. In order to address this challenge, we propose 
quantifying and stratifying models by baseline illness severity at the time of hospital 
presentation. We have received all of the HAIVEN network data for the 2017-18 influenza 
season, which was a particularly severe season. Having all of the network data will improve our 
analysis by giving us increased power to detect differences in influenza severity. In addition, 
these data contain a variety of vitals and laboratory measures collect at hospital admission. We 
will consider variables such as blood pressure, respiratory rate, temperature, blood urea nitrogen, 
sodium levels, glucose levels, hematocrit, partial pressure of arterial oxygen, oxygen saturation, 
white blood cell count, platelet count, creatinine, bilirubin, lactic acid, and Glasgow Coma Scale 
when defining baseline severity. 
In order to quantify baseline severity, either regression shrinkage methods (LASSO, 
ENET) or latent variable modeling will be used. Latent variable modeling would allow us to use 
indicator variables, such as the severity variables, to categorize our enrollees into groups based 
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on an unmeasured latent variable. We could then stratify by this latent variable when examining 
the impact of vaccination and antiviral treatment on severe outcomes.  
Initial examination of the 2017-18 data provides early indication that we will need to 
quantify baseline severity to understand the biases present in this analysis. When we first 
analyzed the 2017-18 data we found that vaccine receipt appeared to be associated with a 
reduction in odds of ICU admission among influenza positive participants (Table 6.1), however, 
this also was the case for influenza negative participants. When we stratified by time from illness 
onset to hospital admission, a measure that could be related to health care seeking behavior and 
severity upon admission, we saw that VE against ICU admission increased among influenza 
positive patients who had onset more than three days prior to hospitalization, but decreased for 
influenza negative individuals (Table 6.2). More evaluation is needed to understand these results. 
Beyond measuring baseline severity, another future direction of this research is to find 
outcomes that more accurately reflect disease severity. When conducting an in-hospital study, 
the outcomes that can be used are limited and none are ideal. ICU admission, which is often 
common enough to use as a severe endpoint, depends on availability of ICU beds in addition to 
physician discretion, which may be related more to other comorbid conditions that the patient 
has than their acute illness. Hospital length of stay, again, may reflect management of comorbid 
conditions, which may or may not be related to the current illness. 
To address this limitation, in the future we would like to conduct follow up surveys and 
detailed assessments of HAIVEN enrollees. We could use survey results to ask questions about 
maximum severity of symptoms, time removed from normal activities, length of symptoms, and 
changes in functional status from admission to a month post-discharge. Receiving more detailed 
outcome information from patients would allow us to have a more detailed understanding of 
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disease course. In addition, we could evaluate which in-hospital outcomes correlate best with 
more robust outcomes to assess whether this extra effort is truly necessary whenever evaluating 
influenza severity among inpatients. 
6.4  Conclusions 
This dissertation examined two main topics, influenza vaccine effectiveness among 
inpatients, and predictors and prevention of severe influenza outcomes. In terms of influenza VE 
in the hospital, we found that the influenza vaccine was effective at preventing influenza among 
children who were fully, but not partially, vaccinated. This evidence supports current guidelines 
recommending that children aged 6 months through 8 years receive two influenza vaccines in 
their first season of vaccination. In addition, we found no evidence of bias due to control group 
selection in test negative design studies among inpatients, supporting the validity of VE 
estimates in this setting. When examining the predictors and prevention of influenza severity 
through vaccination and neuraminidase inhibitor administration, we saw that hospitalized 
patients with obesity were treated with neuraminidase inhibitors sooner after admission than 
other patients, potentially impacting the measured relationship between obesity and influenza 
severity in the hospital. We also saw that in the HAIVEN study, neuraminidase inhibitor 
administration was associated with reduced hospital length of stay among vaccinated, but not 
unvaccinated hospitalized adults. These results lead us to our upcoming analyses, a goal of 
understanding whether this stratification by vaccination status is necessary to assess the impact 
of neuraminidase inhibitor administration on influenza severity due to underlying differences in 
disease severity at hospital admission. These analyses should allow for a better understanding of 
the reduction of influenza severity afforded by vaccination and neuraminidase inhibitor 
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administrations, leading to rapid assessment of new interventions in a pandemic scenario and 
improvement of current interventions.  
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Table 6.1 VE against ICU admission, stratified by influenza positivity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Influenza Positive Influenza Negative 
 VE  95% CI VE  95% CI 
Unadjusted 33.6%  (-5.1%, 58.0%) 27.2%  (8.2%, 42.0%) 
Fully Adjusted 38.3%  (-1.1%, 62.3%) 29.3%  (9.8%, 44.5%) 
Firth’s corrected models. Fully adjusted models are adjusted for sex, age (continuous), race group, 
enrollment site, frailty score (cont), charlson category (1-3, cont), self reported health (poor/fair vs 
excellent/very good/good) 
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 Table 6.2 Influenza VE against ICU Admission, Stratified by Influenza Positivity and Time from 
Illness Onset to Hospital Admission. 
 Influenza Positive Influenza Negative 
Time from Onset to Admission<=3 days VE (%) 95% CI VE (%) 95% CI 
Unadjusted 8.8%  (-71.3%, 50.6%) 33.3%  (14.0%, 50.8%) 
Fully Adjusted 6.7% (-81.7%, 51.2%) 37.0% (15.1%, 53.0%) 
Time from Onset to Admission>3 days     
Unadjusted 54.9%  (10.1%, 77.9%) 9.1%  (-37.4%, 39.1%) 
Fully Adjusted 65.4%  (25.1%, 84.4%) 10.8% (-37.6%, 41.5%) 
Firth’s corrected models. Fully adjusted models are adjusted for sex, age (continuous), race group, enrollment site, frailty 
score (cont), charlson category (1-3, cont), self reported health (poor/fair vs excellent/very good/good) 
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